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ABSTRACT OF THE DISSERTATION 
MULTIFUNCTIONAL NANOPARTICLES FOR THERANOSTIC APPLICATIONS 
by 
Supriya Srinivasan 
Florida International University, 2015 
Miami, Florida 
Professor Anthony J. McGoron, Major Professor 
Multifunctional agents for the management of highly heterogeneous diseases, like cancer, 
are gaining increased interest with the intent of improving the diagnostics and therapy of 
cancer patients. These agents are also important because more than one treatment 
modality is typically used for cancer therapy in the clinic. Further, nanotechnology offers 
a platform where more than one agent can be combined to help provide improved cancer 
diagnosis and therapy. Near-infrared light-activatable phototherapeutic agents have great 
potential in vivo. Body tissues have minimum absorption in the near- infrared range. 
They also have been shown to enhance the cytotoxic effect of chemotherapeutic drugs 
when used in combination with them. We have, hence, investigated the potential of two 
multifunctional targeted nanoparticles for combined chemo-phototherapy (employing 
near- infrared light activable agent) and for understanding their underlying cellular 
responses. The first is employing polymeric Poly-lactic acid-co-glycolic acid (PLGA) 
nanoparticles with simultaneous incorporation of Indocyanine Green (ICG) (a near-
infrared light-activatable photothermal agent) and Doxorubicin (DOX) and surface 
conjugated with anti-Human Epithelial Receptor-2 (HER-2). The PLGA nanoparticles 
were subjected to two modes of hyperthermia, incubator and laser hyperthermia, to 
vii 
 
mimic whole-body and localized hyperthermia used clinically. These nanoparticles upon 
laser exposure showed a rapid heat shock protein 70 (HSP70) response in comparison to 
the cellular HSP70 response upon incubator hyperthermia exposure. However, 12h post-
treatment, downregulation of HSP70, was observed, thus, causing cellular apoptosis or 
necrosis based on the degree of thermal insult. These targeted nanoparticles, 
simultaneously incorporating agents, suffer from the limitation of release of both the 
agents from the nanoparticles and the need to control their release for bringing in 
effective therapy. Therefore, the second multifunctional nanoparticle employing silver 
nanoparticles (AgNPs) conjugated with Doxorubicin was formulated. AgNP serve as a 
near-infrared activatable agent itself, other than serving as a drug delivery vehicle. Thus, 
these nanoparticles only require the need to control the release of DOX alone. We further 
studied their mechanism of action, which included enhanced reactive oxygen species 
(ROS) production and reduction of intracellular thiol levels. 
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1. INTRODUCTION AND REVIEW OF LITERATURE: 
 
1.1 Background and Relevance:  
 
Cancer is the second leading cause of death in USA next to cardiovascular disease. With 
increasing annual cancer incidence and related mortality, it is evolving as a major public 
health problem across the globe. The 5-year relative survival rate for all cancers 
diagnosed has increased from 49% between 1975-1977, to 68% in 2014. In children, a 
higher improvement in survival rates was found due to an increase in current treatment 
methodologies (ACS 2014). Thus, this increasing survival rate among adults and children 
reiterates the need for the development of strategies with higher therapeutic effects at the 
tumor site and lesser negative side effects to normal cells.  
 
The current treatment modalities for cancer include chemotherapy, radiotherapy and 
surgery. These, however, lack specificity towards cancer. Several investigators have 
found that a combination of two or three treatment modalities often have enhanced 
therapeutic outcome compared to the application of a single modality alone (Bozic 2013). 
Delivery of these adjuvant therapies in conjunction with traditional therapies employing 
advanced technologies, can help in an accurate and precise diagnosis through imaging 
and early cancer detection. Novel technologies developed with intent to reduce the side 
effects of primary therapies (such as chemotherapy) and enhance their therapeutic effects 
at the cancer site are thus required. Research efforts geared towards the development of 
multifunctional platforms aim at combining several therapies while providing control 
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over drug release profiles. For instance, a chemotherapeutic agent and a phototherapeutic 
agent could be simultaneously delivered to a target site and activated for a combined 
effect. This approach can help customize treatment schedules, enhance treatment 
planning, and monitor responses to therapy for improved therapeutic outcomes.  
 
Anthracycline drugs are one among the most commonly used chemotherapeutic agents in 
the clinic. These drugs mediate their toxic effect by binding to DNA and impairing its 
replication, and subsequently affecting cell growth. These drugs, however, lack 
specificity, and therefore, exhibit high systemic toxicity (Ferrans 1978). Recent studies 
have shown the application of these drugs in conjunction with several adjuvant treatment 
therapies such as radiotherapy and hyperthermia (Ragaz 1997; Gori 2005). Hyperthermia 
is one among the emerging neo-adjuvant therapies that when used in conjunction with 
chemotherapy is found to have synergistic anticancer effect.  
 
Phototherapy is a therapeutic modality involving light, preferably near-infrared (NIR) 
light, with enhanced tissue penetration and less scattering. These therapeutic agents 
exhibit toxicity only when irradiated. Selectivity of these agents can be gained through 
two methods: 
 
(1) Engineered phototherapeutic agents (nanoscale agents or photosensitizers) can 
selectively get into tumor cells through passive or active means. 
(2) Illumination can be limited only to the diseased site, leaving normal cells 
unaffected. 
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Thus, the selectivity of these agents reduces the systemic toxicity of traditional treatment 
modalities such as chemotherapy. Rapid advancement in the field of nanotechnology has 
raised interest in nanomaterial-based phototherapies (Cheng 2014). 
Two modes of phototherapy are currently used for cancer treatment: photothermal 
therapy (PTT) and photodynamic therapy (PDT): 
PTT employs agents that absorb light and convert it into heat, leading to cell death. Ideal 
PTT agents absorb light in the NIR regime, to which biological tissues are mostly 
transparent. PTT is a form of hyperthermia, which is thermal dose-dependent. The 
preferred temperature for cell killing is 41-43 ºC as these temperatures have shown 
selective toxicity towards tumor cells in comparison to normal cells (Cavaliere 1967). 
Clinical hyperthermia often involves a wide range of temperatures from 39-60 ºC, with 
high temperatures being applied in ablation procedures. Lower temperatures (41-43 ºC) 
often are used as an adjuvant therapy to radiation or chemotherapy 
Treatment outcome based on hyperthermia is also highly dependent on cancer cell type, 
rate of temperature change, duration of exposure, and mode of heat delivery (Urano 
1999). Hyperthermia is found to disrupt proteins and the structure of cancer cells 
(Hildebrandt 2002), and tumor cells are found to be more susceptible to hyperthermia-
based cell killing (van der Zee 2002). Hyperthermia agents for cancer therapy can be 
activated through several ways, such as application of microwave heat, radiofrequency 
waves, and laser (Colombo 1996; Curley 2008; Tang 2013). Among several hyperthermia 
agents under study, organic dyes are gaining wide popularity due to their combined 
hyperthermia and NIR-imaging capabilities. When these organic dyes interact with NIR 
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laser light, they generate heat (a phenomenon which is dye concentration-dependent) and 
can reach temperatures that are cytotoxic to tumor cells (43 ºC). These organic dyes can 
be used as both imaging and photothermal agents, and hence are good candidates for 
theranostic applications. Inorganic nanomaterials such as gold, carbon nanotubes, 
palladium sheets, and copper sulfide nanoparticles have also been reported for their 
photothermal capabilities (Zhou 2010; Gou 2011; Huang 2011; Yang 2013). PTT agents 
can be used in conjunction with other traditional therapies to bring about synergistic 
cancer therapy (Tang 2010), and nanoparticles further decorated with antibodies can help 
improve therapeutic drug indices by enhancing delivery to target sites (Lei 2011; 
Srinivasan 2014).  
 
Photodynamic therapy (PDT) utilizes singlet oxygen or reactive oxygen species (ROS) to 
bring about its cytotoxic effect. The ROS is generated when a photosensitizer interacts 
with light of suitable wavelength, and aids in cell death and tissue destruction (Dolmans 
2003 ). A wide range of photosensitizers have been applied to PDT. However, extensive 
research has proved that nanoparticle based PDT agents are better alternatives over 
traditional PDT agents (Bechet 2008). Various nanomaterials such as polymeric 
nanoparticles (Son 2011 ), magnetic nanoparticles (Yu 2012), and mesoporous silica 
nanoparticles (Tu 2009) have been used for the delivery of photosensitizing agents. 
Recent advances in nanotechnology have included the development of metal plasmonic 
nanoparticles as PDT agents. These nanoparticles exhibit several positive attributes over 
traditional organic dye-based PDT agents, such as higher molar extinction (Brullot 2012) 
and lack of photobleaching (Bonnett 2001). Silver and gold nanoparticles are plasmonic 
5 
 
nanoparticles that can induce a photodynamic effect when interacting with a laser of 
appropriate wavelength and fluence rate. The phototoxicity of a silver nanoparticle 
(AgNPs) is through its oxidation to ions. The ions generated produce reactive oxygen 
species, which in turn cause further degradation of cellular DNA and cytotoxicity 
(Mfouo-Tynga 2014).   
 
PTT and PDT mediate their toxicity through different mechanisms. PTT involves heat 
which interacts with cells through disruption of proteins, whereas PDT involves 
generation of reactive oxygen species that elicits cytotoxicity through cellular DNA 
damage and lipid peroxidation (Rim 2013). Hence, the mechanisms behind both therapies 
provide novel and complementary strategies to cancer therapy and diagnosis. Both PTT 
and PDT involve the disruption of the balance in cancer cells in order to bring about their 
cytotoxic effects. PTT involves disruption of proteins, so the levels of pro-apoptotic 
proteins and anti-apoptotic proteins can help us determine the efficacy of the treatment 
outcome. PDT involves the production of ROS, and hence the balance between cytotoxic 
oxygen species and the anti-oxidant potential of cancer cells needs to be disrupted in 
order to bring about effective treatment outcome. 
 
Heat shock protein 70 (HSP70) and caspase-3 (C3) are important classes of proteins 
which are most widely involved in cell apoptosis. When cells are exposed to external 
environmental stressors, such as chemotherapeutic or hyperthermia agents, protein 
denaturation occurs causing them to be misfolded resulting in an abnormal state. This 
provides stimulus to the cells to express heat shock proteins. These HSP70 help correct 
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misfolded proteins, reverting them to their original state, which further promotes cell 
survival (Ciocca 2005). Caspase-3 (C3), on the other hand, is an important pro-apoptotic 
protein. It is secreted in inactive form in the cells and can be easily converted to active 
apoptotic proteins by death signals provided by death receptor ligands attached to death 
receptors such as Fas, TNFαR, etc., onto tumor cell membranes (Lavrik 2005). A positive 
correlation between cell death and expression of C3 has been found (Porter 1999). Thus, 
the expression of HSP70 and C3 affects the therapeutic efficacy of PTT in combination 
with chemotherapy. 
                                   1.2. REVIEW OF LITERATURE:  
1.2.1. Mode of action of chemotherapeutic agent (effects vs. side-effects):  
 
Anthracycline drugs such as Doxorubicin (DOX), Daunorbicin etc., form a class of 
chemotherapeutic agents widely used for the treatment of a broad spectrum of cancers 
such as breast, ovarian and colorectal (Buzdar 1985; Singal 1998). These anthracycline 
drugs mediate their cytotoxicity by intercalating with the DNA in the nucleus of cancer 
cells. These drugs inhibit the activity of DNA topoisomerases which plays a major role in 
DNA replication (Tewey 1984). Despite their potent antitumor activity, their clinical 
application is limited by their dose-dependent toxicity to normal cells (Jeyaseelan 1997). 
One of the main mechanisms of toxicity of DOX in normal cells is through the generation 
of reactive oxygen species, which in turn damages mitochondrial DNA (Menna 2007). 
Among all the healthy cells, cardiac cells are most affected by DOX dosing due to their 
high mitochondrial content (Chen 2007).  
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Increasing dose administration of these drugs has often been correlated with increasing 
occurrence of drug resistance among tumors. Several non- transport and transport based 
mechanisms are implicated for this drug resistance, of which the role of drug efflux 
proteins expressed on tumor cell surfaces is the most studied model for such phenomena 
(Feng 1992). Anthracycline drugs such as Doxorubicin are important substrates to these 
efflux protein pumps which thereby reduce their anti-tumor efficacy. Thus development 
of approaches in order to reduce the non-specific toxicity and revert the drug resistance of 
these agents is essential for enhanced chemotherapeutics- based treatments.  
 
1.2.2. Approaches to reduce side-effects and improve treatment efficacy:  
 
1.2.2.1. Drug- antibody conjugates:  
 
Cytotoxic chemotherapeutic agents have clinically improved the survival of patients with 
several classes of cancer such as breast, ovarian, uterine and lung (Loehberg 2005; Pisano 
2005). Mixtures of several chemotherapeutic drugs are used to treat several aggressive 
and malignant tumors (Kalwinsky 1991). However, these drugs exhibit low therapeutic 
index due to their non-specificity to tumor cells. These agents also accumulate in normal 
cells and thus their availability at the tumor site is reduced. A narrow margin between the 
efficacious and toxic doses of these drugs is created which prevents the administration of 
a higher dose of these drugs required to eradicate the tumor.  
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This problem can, however, be circumvented by a strategy proposed in 1906 by Ehrlich 
using the so-called “magic bullet” (Ehrlich 1906). According to Ehrlich, a magic bullet 
would comprise of a therapeutic agent conjugated to an organ specific carrier. The organ 
specific carrier can be an antibody, aptamer or other small molecule that specifically 
recognizes a tumor specific antigen, often overexpressed on the surface of tumor cells. 
This strategy would help in the accumulation of drug at the tumor site and minimize 
exposure to normal cells (Ehrlich 1906). Some examples of tumor associated antigens 
(TAAs) are Human Epithelial Receptor-2 (Molinaa 1997), Folate receptor (Sudimack 
2000; Reddy 2005), transferrin (Högemann-Savellano 2003), CD22 (Matsushita 2008), 
and Prostate Specific Membrane Associated antigen (PSMA) (Gao 2004). A few 
therapeutic agents targeted to tumor associated antigens which have been approved by the 
FDA are Mylotarg for acute myelogenous leukemia (Sievers 1999), Ontak for cutaneous 
T-cell lymphoma (Kreitman 2003) and Bexxar for non-Hodgkin's lymphoma (Zelenetz 
2003).  
However, conjugation of a chemotherapeutic agent directly onto antibodies or small 
ligands (like folic acid) allows for attachment of very few drug molecules. Thus, this 
method requires a higher amount of drug immunoconjugate (or ligand- based conjugates) 
to be administered for the desired therapeutic effect at the target tumor site (Jaracz 2005). 
The potency of these conjugates depends on the specificity of the antibody or small 
molecule ligand  to the TAA, the potency of drug molecule and the linker between the 
antibody/small molecule ligand and drug molecule (Carter 2001). High molecular weight 
drug immunoconjugates (or ligand- based conjugates) can be targeted to tumors through 
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the Enhanced Permeation Retention Effect (EPR) effect. However, they are often unable 
to penetrate solid avascular tumors. Diffusion is the major mode of transport in solid 
avascular tumors. Flux (diffusion) inside solid tumors largely depends on the diffusion 
coefficient of the molecule itself. According to the Stokes- Einstein equation, a direct 
relationship exists between diffusive flux and the diffusion coefficient of molecules 
(Miller 1924). High molecular weight molecules have smaller diffusion coefficients and 
thus, have a lower penetration in solid avascular tumors (Pluen 2001). Low molecular 
weight drug-immunoconjugates (or ligand-based conjugates) created by employing 
truncated antibodies (those formed by truncating the Fc portion of the antibody to have 
Fab conjugated to drug molecules), on the other hand, can more easily penetrate solid 
tumors. However, they are cleared faster by the kidneys (Hansson 1988).  
1.2.2.2 Prodrug- based therapies: 
A prodrug is a drug which is non-toxic and inert, and becomes pharmacologically active 
when metabolized inside the body. Prodrugs are used when the active form of drug is 
insoluble in plasma or unstable and easily metabolized before it reaches the target. 
However, this concept is different from drug loaded carrier or drug vehicle. Some of the 
advantages of prodrug-based cancer therapies are increased drug stability, overcoming 
drug resistance, improved pharmacokinetics, and selective activation in target cells 
(Connors 1986).   
 
Prodrugs in cancer therapy help in improving selectivity of the drug to tumor cells by 
being selectively activated in tumors. Prodrug-based strategies for selectively delivering 
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chemotherapeutics are based on the unique aspects of tumor physiology, such as selective 
enzyme expression (Xu 2001), hypoxia (Denny 2000), and low intracellular pH (Fan 
2013). Prodrugs are based on externally-supplemented compounds which can selectively 
be activated in tumors. Exogenously supplemented prodrug-based strategies include those 
directed through monoclonal antibodies (Antibody directed enzyme prodrug therapy, 
ADEPT) or DNA constructs (Gene directed enzyme prodrug therapy, GDEPT) (Xu 
2001). 
 
Several prodrug based strategies for selective delivery of DOX into tumors have been 
investigated. For instance, Albright and coworkers investigated tumor-selective delivery 
of DOX through a peptide-based DOX prodrug. The prodrug was activated by the 
combined proteolytic action of extracellular and intracellular enzymes MMP-2, MMP-9 
and MMP-14. Briefly, the prodrug was comprised of an Ac–Glu–Pro–Cit–Gly–homo-
Phe–Tyr–Leu–DOX sequence, which under the combined action of the above mentioned 
enzymes could selectively cleave the prodrug to release DOX in tumor cells. The prodrug 
demonstrated selective delivery of DOX in in vitro and in vivo in xenograft models. It 
also exhibited a 10-fold tumor/heart distribution, thus reducing the inherent cardiotoxicity 
of DOX (Albright 2005). Another example of a prodrug-based strategy for DOX delivery 
was reported by Biela and coworkers. Their group utilized an antibody-directed enzyme 
prodrug based strategy, based on the application of Tumor Necrosis Therapy (TNT) 
monoclonal antibodies (MAbs) for selective delivery of DOX to necrotic tumor regions. 
Briefly, fusion proteins of single chain Fv (scFv), Fab or F(ab’)2 fragments of chimeric 
TNT-3 and the human beta-glucuronidase (betaG) enzyme were constructed. These 
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constructs were used to make a glucuronide prodrug conjugate of DOX. When the 
efficacy of the prodrug was tested in vivo, the results showed that the BetaG enzyme in 
the construct could specifically localize in tumors and was active for up to 9 days. Fusion 
protein dose administration after prodrug administration demonstrated active tumor 
cytotoxicity without systemic toxicity (Biela 2003). 
 
Thambi and coworkers reported a tumor hypoxia-based prodrug for selective delivery of 
DOX. Hypoxia-responsive nanoparticles were created by conjugating hydrophobically 
modified 2-nitroimidazole derivative to the backbone of carboxymethyl dextran (CM-
Dex). DOX was encapsulated into these nanoparticles. These nanoparticles exhibited 
sustained release under normoxic conditions, and significantly increased drug release 
under hypoxic conditions. These drug encapsulated nanoparticles exhibited high 
antitumor efficacy in vivo (Thambi 2014). 
 
Tumor pH has also been investigated as a target strategy to selectively deliver 
chemotherapeutic drugs, especially DOX. One of the first attempts to employ pH-
sensitive linkages for tumor selective delivery of DOX was made by Zhou and 
coworkers. They developed poly(ethylene oxide)-graft-doxorubicin (PEO-g-DOX) 
prodrugs, with DOX covalently conjugated to PEO via a pH-sensitive hydrazone bond. 
When compared with free DOX in vivo, these prodrugs had significantly prolonged 
circulation time and enhanced drug accumulation in the tumor (Zhou 2011). Several other 
investigators have developed pH-targeted prodrug systems employing different pH-
12 
 
responsive polymers and pH-sensitive linkages in particular for tumor delivery of DOX 
(Du 2013; Zhang 2014).  
 
HPMA-doxorubicin-galactosamine (known as PK2) is a targeted prodrug for DOX that 
has entered clinical trials. This prodrug is targeted towards asialoglycoprotein receptor 
(ASGPR), which is selectively expressed in hepatocytes and hepatoma cell lines. 
Preclinical trials employing rodent models have shown selective release of DOX in 
tumors, with a fivefold reduction in cardiotoxicity in comparison to free DOX after 
intravenous or intraperitoneal administration at several doses. The prodrug also showed 
several positive attributes over its corresponding drug DOX in Phase I/II trials, with 12-
to-50 fold increased tumor concentration compared to free DOX. Thus, this prodrug 
holds huge promise for advancing to the next stages of clinical trials (Seymour 2002).  
 
Based on current research, a major advantage of prodrug based strategies is their target 
selectivity and reduced systemic toxicity, which makes them ideal for clinical 
applications  
1.2.2.3. Adjuvant therapies:  
Adjuvant therapies are referred to as those therapeutic modalities which are often co-
administered along with a primary mode of treatment. These therapies, when 
administered along with the primary treatment method, can help enhance the therapeutic 
effect of the primary therapy (i.e., synergism). Several adjuvant therapies are used in 
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conjunction with chemotherapy, such as radiotherapy (Ragaz 1997), hormonal therapy 
(Solomayer 2003) and surgery (Felip 2010).  
 
Hyperthermia is a neo-adjuvant therapy, and when applied along with chemotherapy and 
other traditional therapies bring about a synergistic therapeutic effect (Issels 2001). 
Hyperthermia (41-43 °C) when used as an adjuvant therapy selectively kills tumor cells. 
Healthy cells are less susceptible to heat than tumor cells (van der Zee 2002). Thus, lower 
hyperthermia temperatures can also help in tumor cell killing, when used in conjunction 
with other treatment modalities. Hyperthermia often denatures proteins and disrupts 
structures inside the cell (He 2004). Hyperthermia can either be administered to the 
whole body or localized (by administering photothermal agents directed to local areas) 
(Xi 2001; Latorre 2009). Several inorganic nanoparticles, such as gold or magnetic 
nanoparticles, have been investigated for the application of heat (Latorre 2009). 
However, these nanoparticles often suffer from the limitation of poor biodegradability. 
Near infrared (NIR) dyes are widely investigated due to their good biocompatibility, 
biodegradability and ability to produce NIR fluorescence light and heat upon excitation, 
using a laser of appropriate wavelength. Indocyanine Green (ICG) is one such dye 
(Dzurinko 2004; Sakka 2007). The only challenge in using ICG clinically is its poor 
aqueous stability and short plasma residence time. Research has focused towards 
entrapping this drug into nanoparticles (Saxena 2004; Manchanda 2010). In our lab, we 
developed multifunctional nanoparticles entrapping ICG and DOX simultaneously into 
PLGA nanoparticles, which were successfully able to revert P-gP resistance mechanisms 
(Tang 2010). 
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Photodynamic therapy (PDT) has also been used by some investigators as an adjuvant 
therapy, including PDT and chemotherapy (Rigual 2013), PDT and surgery (Baas 1997) 
and PDT and immune therapy (Castano 2006).  PDT has been used in combination with 
several classes of chemotherapeutic drugs, such as alkylating agents (He 2009), drugs 
targeting topoisomerases (Peng 2009), drugs targeting the cytoskeleton (Dima 1990), 
antimetabolites (Hatse 1999), and antitumor antibiotics (Ma 1992). Among several 
antitumor antibiotics, DOX is the most widely used chemotherapeutic agent for the 
treatment of a broad spectrum of tumors, and has been utilized in conjunction with PDT. 
For example, Canti and coworkers investigated the effects of combinatorial therapy 
consisting of disulfonated aluminium phthalocyanine (a known PDT agent) along with 
DOX on leukemia-bearing mice, and found a significant additive antitumor effect for the 
combination treatment (Canti 1998). 
Photodynamic therapy employs photosensitizers which mediate their toxicity upon laser 
exposure. Photosensitizers in PDT help transform light energy to a type II chemical 
reaction. The reactive end products in the reaction pathway result in rapid cytotoxicity. 
Recently, several researchers have helped in creating imaging and laser technologies to 
measure effective dose of photosensitizers with high ROS turnover in vivo. There are 
several photosensitizers that are clinically available, for example, Photofrin (Axcan 
Pharma inc, Birmingham, IL), Metvix (Galderma, Ft. Worth, TX) Photochlor (Medkoo 
Biosciences, Chapel Hill, NC), etc. The different photosensitizer families that have been 
widely investigated for PDT include the porphyrin and chlorophyll platforms, and dyes 
such as phthalocyanine and napthalocyanine (Allison 2004). These photosensitizers are 
referred to as first-generation photosensitizers, and suffer from several limitations such as 
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poor light absorption, cutaneous photosensitivity, and possible photobleaching effects. 
Thus, there is a need for the development of novel photosensitizers to address these 
problems and improve the efficacy of PDT. This could be achieved by structural 
modification of existing photosensitizers, or by developing new photosensitizers with 
different cytotoxicity mechanisms. Other researchers are exploring the development of 
new non-porphyrin, non-traditional photosensitizer agents (O'Connor 2009 ). For 
example, plasmonic nanoparticles can be used as photosensitizers upon appropriate laser 
irradiation and fluence rate (Vankayala 2013).  
1.2.2.4. Image- guided therapy (IGT): 
Surgery is the first line of treatment for most solid tumors. During resection, some tumors 
do not require a clear demarcation between tumor and normal tissues because a portion of 
healthy tissue can be resected without complications, or because the boundary of the 
tumor is distinct. For example, this is the case in early skin cancer. Certain surgeries, 
however, require much more precise differentiation between tumor and normal cells. This 
is true in tumors where cancer cells invade nearby tissues, such as breast cancer; or in 
cases where critical structures may be located near tumor cells so that a meticulous 
choice of resection boundaries is crucial, for instance in brain tumors. Probes that can 
provide visual differences between tumor and normal tissue would help in such surgeries. 
Image-guided therapy, or IGT, exploits imaging modalities to help localize and target 
therapeutic agents in the diseased tissue and monitor and control treatment. Targeted 
labeled probes (mostly guided through different imaging modalities) also help reduce the 
chances of leaving residual tumorous tissue behind after surgery, and facilitate the 
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assessment of tumor prognosis. Over the past decade, image-guided surgeries have 
evolved from traditional invasive approaches into applying minimally invasive imaging 
modalities. Advanced imaging modalities such as Magnetic Resonance Imaging (MRI), 
Computer Tomography (CT) and Positron Emission Tomography have replaced the 
routine X-ray (Jolesz 2014). Different imaging modalities that can be used in image-
guided therapy or surgery are described in the next sections. 
1.2.2.4.1. Image-guided Radiation Therapy (IGRT): 
The specific containment of radiation doses in a clinical target has been a longstanding 
challenge in the practice of radiation oncology. Recent technological advances have 
helped in estimating dose distribution in tumors with great accuracy and precision. The 
appropriate choice of imaging modality is of utmost importance, since resolution and 
contrast of images can greatly alter the assessment of treatment outcomes and the ability 
to accurately monitor the progress of radiotherapy. There are two imaging modalities 
which are currently available for use in IGRT: Ultrasound (US) and Computerized 
Tomography (CT). Ultrasound is a technology which provides soft-tissue contrast at low 
cost with no known side effects, in comparison to more expensive modalities such as 
Computerized Tomography. However, it suffers from the limitation of required acoustic 
coupling, which necessitates physical contact between the probe and the patient’s 
external contour (Djemil 2007). CT-based scanners help in imaging and helical delivery 
of Intensity Modulated Radiation Therapy (IMRT). Image-guidance in this technique is 
achieved by employing low energy x-ray and a CT-detector. The imaging capacity of this 
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technology is highly integrated with automatic alignment, and has the capacity to correct 
for rotations about the superior-inferior axis of the patient (Mackie 1999; Welsh 2002). 
A major drawback of IGRT is the use of ionizing radiation and potential high cost of 
some of the technologies. This has caused researchers to investigate other forms of 
image-guided therapy which do not have these shortcomings.  
 
1.2.2.4.2 Fluorescence- guided therapy: 
 
Optical imaging is a technology which uses light produced by biological or chemical 
moieties, and is gaining utmost importance in biomedical applications because it employs 
non-invasive and non-ionizing radiation (Balas 2009). Fluorescence imaging is the most 
widely used form of optical imaging, which is described in the subsequent section with 
respect to its application in guiding surgeries. 
The phenomenon of fluorescence was first described by British scientist Sir George G. 
Stokes, who coined the term after observing fluorescence from the mineral “fluorspar”. 
Fluorescence is characterized by the emission wavelength being longer than the 
excitation (absorbance) wavelength, also known as Stokes shift. It could be argued that 
fluorescence imaging has now emerged to be the most important phenomenon in modern 
biology and medicine. Specific fluorescence staining boosted its application in early last 
century, and fluorescence microscopy raised its prominence further with the invention of 
immunofluorescent staining and functional imaging. The possibility to create living 
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material with targeted expressible fluorescent proteins revolutionized fluorescence 
microscopy to the next level. 
In vivo and in vitro fluorescence imaging is similar in several aspects, such as the use of a 
low-light camera and appropriate filters to collect fluorescence from samples. However, 
in vivo fluorescence imaging is more complex than in vitro fluorescence imaging. 
Practical concerns during in vivo imaging involve strong absorption and scattering effects 
in animal tissues which obscure signal collection and quantification. The biologically 
complex in vivo environment presents additional challenges in terms of stability of 
fluorescent probes and their selective accumulation in target tissues (Rao 2007). 
Fluorescence-guided surgery is currently under investigation in clinical trials. It has been 
proved that 5-aminolevulinic acid (5-ALA) induces localization of fluorescent porphyrins 
in glioblastoma, which can be exploited for potential tumor resection (Stummer 2000; 
Stummer 2006). Clinical trials have been conducted to analyze the effects of 
fluorescence-guided resection on postoperative magnetic resonance (MR) imaging and 
survival in patients undergoing surgery (Stummer 2000; Stummer 2006). Additional 
examples include the application of fluorescently labelled protease-sensitive probes to 
improve tumor detection in animal models (Sheth 2009), and the use of activatable cell-
penetrating peptides responsive to tumor-associated matrix metalloproteinases (MMP) 
which have been shown to improve tumor resection in breast tumor and melanoma-based 
animal models (Jiang 2004). 
 
19 
 
Fluorescence can be measured if fluorophores are expressed by specific modified genes 
or tagged onto specific molecules and/or biomolecules. This technique, however, has 
certain limitations such as photobleaching in long-term studies, as well as the potential 
for disadvantageous modifications in the properties of the tagged molecule of interest. 
1.2.2.4.3 Raman Spectroscopy based image – guided therapy: 
Raman spectroscopy is a non-invasive, label-free technique which is a feature of 
vibrations of molecular bonds. Monochromatic light interaction with materials results in 
two types of scattering: elastic and inelastic. When the energy of the scattered photons is 
different from that of the incident photon, this is known as inelastic or Raman scattering, 
and Raman spectroscopy is the method of measuring and analyzing these scattered 
photons. Fourier Transform Infrared Spectroscopy employs a similar technique for 
molecular characterization. However, it is dependent on low power sources and noisy 
detectors. Infrared spectroscopy suffers from low penetration in aqueous solution, making 
it unsuitable for biological specimens. Raman spectroscopy can employ lasers with 
wavelength in the near-infrared region, which facilitates in vivo imaging. The sub-cellular 
resolution achieved through this technique is comparable to fluorescence imaging and far 
superior to several medical diagnostic techniques, such as ultrasound, magnetic resonance 
imaging, Positron Emission Tomography, or X-ray imaging. The light emitted is red- 
shifted to lower wavelengths and can be recorded by a charge-coupled device (Downes 
2010).  
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Near-infrared Raman Spectroscopy is a powerful analytical tool used in detecting 
important differences between biological samples without interference from 
autofluorescence. It has been suggested as a tool for cancer screening (Mahadevan-Jansen 
1998; Huang 2003). Raman spectroscopy in the near-infrared range is also a very useful 
technique in providing quantitative diagnostic information about the tissue under study. 
Progression of a disease is accompanied by chemical changes in the tissue associated 
with it, making Raman spectroscopy a useful tool to diagnose disease progression. 
Raman spectroscopy can be performed in vivo using optical fibers incorporated in 
catheters, endoscopes and cannulas (Hanlon 2000). Raman signals generated from 
samples are often very weak due to strong background emission due to fluorescence, 
which would make them completely undetectable (Kim 2010). However, statistical 
algorithms can be employed to distinguish the spectra of different samples.  
 
Raman spectroscopy has been used as an in vivo image-guiding tool to assess spectral 
features of nasopharyngeal and laryngeal tissue during clinical endoscopic examination. 
A 785-nm Raman endoscopy system along with a miniaturized Raman probe was used 
for real time Raman measurements of different anatomical regions of the head and neck. 
Raman spectral differences between different components of the nasopharynx and larynx 
were used as important parameters for interpretation, and utilized to analyze decision 
algorithms for in vivo tissue diagnosis and characterization (Bergholt 2012). Raman 
spectroscopy with a diagnostic detection algorithm has also been used for nasopharyngeal 
carcinoma diagnosis and detection in vivo (Vankayala 2013).  
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Surface-Enhanced Raman Scattering (SERS) is a method that can be used to increase 
Raman signals without employing complex algorithms. This technique uses metal 
nanoparticles to enhance the Raman signal. A massive enhancement of the 
electromagnetic field around the nanoparticle surface occurs based on size and geometry, 
causing an enhancement up to the order of 14 recorded till date (Huh 2009).  
 
SERS is a newly emerging field for biomolecule detection (Li 2004; Han 2009). It is 
based on the principle of interaction of electromagnetic waves with a metal surface. 
When metal surfaces are rough or occur at junctures, the wave may excite the surface 
plasmons on the surface causing amplification of electromagnetic fields near the metal 
surface. This causes a large enhancement of the Raman scattering. Chemi-adsorbed 
molecules exhibit chemical SERS enhancement in their Raman signal (Moskovits 1985).  
 
SERS technology exhibits several positive attributes, such as high sensitivity and 
multiplexing capabilities that help in in vitro cancer detection. The most common 
approach involves immunoassays for recognition of cancer cell-surface biomarkers with 
their complimentary antibody-conjugated SERS substrates. This technique overcomes the 
limitations of currently used immunoassays, such as extended incubation time and the 
need for repeated washings (Chon 2009). SERS was initially investigated as a non-
invasive modality for in vivo cancer imaging using colloidal gold nanoparticles with 
organic dye based Raman reporters in mice (Qian 2008). Single-walled carbon nanotubes 
selectively targeting integrin-positive U87MG tumors can be imaged in vivo in mice 
using SERS (Keren 2008). Gold nanoparticles with selective NIR SERS reporters can 
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selectively image HER-2 positive tumors in vivo (Maiti 2012). Current research 
approaches are intended to exploit the multiplexing capabilities of SERS nanotags to 
track tumors in vivo (Zavaleta 2009). 
1.2.2.5. Nanotechnology based methods:  
Drug delivery research focuses on the development of targeted delivery of 
chemotherapeutics and other cancer therapeutic drugs. An ideal drug delivery vehicle is 
the one which entraps high drug payload and is able to deliver it specifically at the tumor 
site with minimal accumulation in normal cells. Nanotechnology is a fast-developing 
field with the potential to converge detection, analysis and treatment of cancer in a 
simultaneous manner (Srinivas 2002; Ferrari 2005). Theranostics is a term that refers to 
the combination of diagnostics and therapeutics on a single platform (Fernandez-
Fernandez 2011; McGoron 2014). Drug entrapped delivery vehicles have been found to 
overcome multi-drug resistance in several cancers (Soma 2000 ). The drugs which are 
substrates of drug efflux proteins enter the cells entrapped, hence evade exposure to these 
proteins (Szakács 2006). Several nanoparticles entrapping chemotherapeutic agents have 
been found to possess the potential to avoid resistance in drug resistant cells, thus 
increasing intracellular accumulation of the drug and hence inducing a higher toxic effect 
(Bennis 1994). Nanoparticles with size 100-200 nm possess the ability for controlled 
drug release, longer plasma residence, and exit leaky tumor vasculature to be taken up by 
tumor cells (Yuan 1995). The gaps in endothelial lining in tumor capillaries range from 
100-600 nm. Thus nanoparticles in this range are suitable to penetrate through tumor 
capillary linings and avoid uptake by macrophages of the reticulo-endothelial system 
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(RES) (Cho 2008). Targeted nanoparticles have also been prepared by modifying the 
surface of the particles with antibodies so that they can selectively target tumor cells over 
expressing the corresponding receptor (Lei 2011). However, these nanoparticles have 
much less diffusion into solid tumors with high packing density due to their low 
diffusivity (Kostarelos 2004). 
 
The drug delivery vehicles used so far for cancer applications are often composed of 
natural and synthetic polymers in the form of nanoparticles, metal and semiconductor 
nanoparticles (Huff 2007; Sarah 2010), micelles (Iyer 2007; Gou 2011), dendrimers 
(Majoros 2005; Peer 2007; Yellepeddi 2009) and liposomes (Takeuchi 2003; McGoron 
2014). Polymeric nanoparticles are widely used due to their several favorable 
characteristics such as biocompatibility, biodegradability, reduced toxicity and 
availability of functional groups for further surface modification (Pridgen 2007; Bhattarai 
2010; Rejinold 2011). Polymeric nanoparticles are prepared through different methods 
which can be broadly classified into two classes; first, by polymerizing monomers and 
further emulsifying the polymers at an interface between aqueous/ organic phase; second, 
based on emulsifying pre- formed polymers (Ganapathy 2009). Nanoparticles that are 
formed by pre-formed polymers can be prepared using different techniques such as 
salting- out, double emulsion preparation, emulsification diffusion and emulsification - 
solvent evaporation methods (Allémann 1992; Desgouilles 2003; Cohen-Sela 2009). The 
ideal method of preparation of polymeric nanoparticles depends on the 
hydrophobicity/hydophilicity of the polymer and drugs.  
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Polyesters are widely used synthetic polymers for delivery of cancer therapeutics; 
because ester bonds are highly acid -labile. This property of these polymers aids in their 
higher degradation in acidic vacoules and hence higher drug release inside the cells after 
their uptake (Anderson 1997). PLGA, which is an FDA approved polymer for various 
biomedical applications, is one such polyester polymer (Lü 2009). This polymer has been 
found to be favorable to carry drugs due to its high biodegradability and biocompatibility. 
The lactic acid and glycolic acid (the monomers of the polymer, PLGA) ratio can be 
easily engineered. The biodegradation products of the polymer; lactic acid and glycolic 
acid; are important components of cell metabolism and hence, nontoxic. PLGA has been 
used for delivery of drugs/genes and proteins (Ruhe 2003; Bivas-Benita 2004; Klose 
2008). This polymer can entrap both hydrophilic and hydrophobic drugs. Hydrophobic 
drugs such as doxorubicin, paclitaxel etc., and hydrophilic molecules such as genes and 
proteins have been extensively studied by researchers (Ruhe 2003; Bivas-Benita 2004; 
Klose 2008; Xu 2008; Lei 2011).  
 
Noble metal nanoparticles, especially gold (Au) and silver (Ag) formulations, exhibit 
unique and tunable optical properties on account of their surface plasmon resonance 
(SPR). The strongly enhanced SPR scattering from Au and Ag nanoparticles makes them 
useful as bright optical tags for molecular-specific biological imaging and detection using 
simple dark-field optical microscopy. The SPR absorption of the nanoparticles has 
allowed their use in selective laser phototherapy of cancer. SPR frequencies are sensitive 
to the dielectric constants of local medium and can be used for sensing of chemical and 
biological analytes (Jain 2007). 
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Nanoparticles can help deliver CT, MRI, nuclear, and optical imaging agents (Lee 2008; 
Kang 2010). Multifunctional nanoparticles further allow for simultaneous in vivo delivery 
of diagnostic (or imaging) and therapeutic agents (Kim 2010). The intrinsic properties of 
nanoparticles can be exploited in some cases for imaging and/or hyperthermia or 
photodynamic therapy (Fernandez-Fernandez 2014; Lei 2014; Mfouo-Tynga 2014; Lei 
2014). This helps in generating integrated theranostics systems which allow for image-
guided therapy. For example, Au nanoparticles have been simultaneously used for dark 
field microscopy, photoacoustic imaging, and hyperthermia applications (Huang 2006; 
Eghtedari 2007). 
 
1.2.2.6 Multifunctional nanoparticles based approaches:  
 
Multifunctional nanoparticles serve as a unique platform for simultaneous entrapment of 
an imaging molecule and therapeutic molecule, thus creating a new phase of developing 
theranostic agents (McGoron 2014). Thus, these multifunctional nanoparticles can allow 
for improved diagnostics and therapeutics. Further, surface engineering of these 
nanoparticles with antibodies can also achieve active targeting. Traditional in vivo 
imaging probes include Positron Emission Tomography (PET) (Phelps 2000), Single 
Photon Emission Computed Tomography (SPECT) (Chatziioannou 2005) and Magnetic 
Resonance Imaging (MRI) (Abraham 1996). Recently developed nano-sized imaging 
probes such as quantum dots and near infra- red dyes are gaining popularity as there is no 
exposure of ionizing radiation (Joshi 2010). Optical imaging systems based on light have 
higher temporal resolution and sensitivity and are less expensive in comparison to 
26 
 
traditional techniques (Fujimoto 1999). However, visible light is absorbed and scattered 
by tissue to a much greater extent than is ionizing radiation (Simpson 1998). Imaging 
probes based on quantum dots are often found to be toxic in vitro and in vivo, depending 
on their characteristics such as size, charge etc., (Hardman 2006). Therefore, near infra-
red (NIR) light is preferred as they evade absorption by biological chromophores and 
hence have higher tissue penetration and many are non-toxic to biological tissues 
(Lammertyn 2000). Thus, nanoparticles entrapping NIR dyes can be easily used for in 
vivo imaging, tailored for surface modification and easily extravasate into tumors through 
their leaky vasculature (Yuan 1995). Some of the dyes belonging to the class of NIR dyes 
can also be used for phototherapy due to their unique heat generation properties (Genina 
2003). Tricarbocyanine dyes such as pthalocyanine, is one such class of dyes which 
possess both imaging and heat generation capabilities (Nelson 1988). Indocyanine Green 
(ICG), which is FDA approved for several clinical applications, is another NIR dye 
belonging to the same class (Dzurinko 2004; Sakka 2007). This dye has photodynamic, 
photothermal and imaging capabilities (Chen 1995; Bäumler 1999; Kitai 2005). Cronaine 
dyes are another class of NIR dyes which have photothermal capabilities and can be 
utilized for in vivo imaging. (Spence 2013, ). Therefore, nanoparticles entrapping these 
dyes which have simultaneous imaging and therapeutic properties serve as ideal agents 
for cancer theranostics. Nanoparticles can also serve as a common platform wherein such 
theranostic NIR dyes can be simultaneously entrapped with other therapeutic agents such 
as chemotherapeutics to synergistically control tumor cell growth (Tang 2010; Srinivasan 
2014; Manchanda 2010).  
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Targeted photodynamic therapy based on multifunctional nanoparticle platforms is 
gathering increased interest for in vitro and in vivo applications. These nano-platforms 
exhibit high surface to volume ratios which help encapsulation and/or coupling of several 
photoactivatable units for PDT, and also allow for tumor sequestration via passive and 
active targeting. Further, contrast agents can also be incorporated into these structures 
(Roy 2003). 
 
1.2.2.6.1. PLGA nanoparticles based multifunctional approaches:  
 
PLGA (Poly-l-lactide-co-glycolide) is an FDA approved copolymer, widely used for drug 
and gene delivery (Bala 2004). Several multifunctional approaches to converge different 
treatment therapies have been investigated by researchers. PLGA nanoparticles can be 
functionalized with Polyethylene glycol (PEG), which provides more stealth, wherein the 
circulation time of nanoparticles can be enhanced. These stealth nanoparticles can also be 
entrapped or conjugated with anticancer agents and further surface functionalized with 
ligands corresponding to the tumor associated antigens for active tumor targeting (Song 
2005). Multifunctional PLGA nanoparticles incorporating anti-cancer agents along with 
other treatment agents aid in synergistic anticancer therapy. For example, Wang and 
coworkers simultaneously entrapped Doxorubicin and Paclitaxel into PLGA 
nanoparticles for enhanced anti-tumor efficacy (Wang 2011). PLGA nanoparticles have 
also been used for the co-delivery of drugs such as Vincristine and Quercetin, 
Indocyanine Green and Doxorubicin etc., in order to achieve synergistic cancer therapy 
(Song 2008; Tang 2010; Srinivasan 2014; Manchanda 2010). Several antibodies, such as 
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Human Epithelial Receptor-2, transferrin etc., have been conjugated to this polymer in 
order to achieve active targeting to tumor. Antibody-polymer conjugates are highly 
immunogenic based on the molecular weight of the antibody and are prone to reticulo-
endothelial system capture (Duncan 2003; Srinivasan 2014).  
 
1.2.2.6.2 Plasmonic- based multifunctional nanoparticles: 
 
Nanoparticles with more than one functionality often prove to be advantageous for 
several bioapplications. Multifunctional plasmonic nanostructures frequently combine 
desirable plasmonic properties along with other functionalities, such as aqueous 
dispersibility and high optical stability, and can be detected through more than one 
sensing modality. The performance of such nanoparticles can be enhanced by the 
combination of therapy and diagnostic agents, making them good candidates for in vivo 
theranostic applications and non- or minimally-invasive cancer therapies (Kreibig 1995). 
 
1.2.2.6.2.1. Silver nanoparticles for cancer therapy: 
 
In the past few decades, there has been increasing interest in the use of Silver 
nanoparticles (AgNPs) in the field of biomedicine and healthcare. These nanoparticles 
have found their applications in rapid wound healing and as potent antimicrobial agents 
(Ip 2006; Tian 2007). The potential of these nanoparticles as drug delivery vehicles is 
also promising, as their large surface area can help deliver large drug doses (Yih 2006). 
Both AgNPs and AuNPs can be used for cell imaging due to their unique property of SPR 
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(Paul 2011), and these imaging capabilities can be used to support early diagnosis. Early 
detection of tumors helps manage and prevent invasion of surrounding tissues and 
improve subsequent prognosis. AgNP with folate conjugation and p-aminothiophenol 
reporter could selectively produce SERS signals in folate receptor overexpressing ovarian 
cancer cells (Boca-Farcau 2014). AgNPs have been used as contrast agents for 
photoacoustic imaging and image-guided therapy, and can be detected ex vivo in 
pancreatic tissue using combined photoacoustic and ultrasound imaging when exposed to 
an 808 nm laser (Homan 2010). These nanoparticles hold promise to selectively hone in 
on tumor cells through the enhanced permeation-retention effect, and may further be 
selectively targeted to tumor cells through the conjugation of tumor-selective ligands 
onto the nanoparticle surface (Liu 2007).  
  
Mahmood and coworkers showed that AgNPs, when used in conjunction with 
chemotherapeutic agents such as etopside, enhance tumor toxicity in comparison to 
AgNP or the drug alone. However, the drugs applied along with AgNP could not confer 
tumor selectivity (Mahmood 2010). Therefore, specific conjugation of tumor selective 
ligands to such treatment can help bring about selective response in tumor cells. 
 
Angiogenesis is the process of development of new blood capillaries to supply oxygen 
and nutrients to growing tissue, and it is critical for cancer progression (Carmeliet 2005). 
Hence, considerable research has been focused towards the development of angiogenesis 
inhibitors that could reduce the supply of oxygen and nutrients to tumors and further aid 
in tumor cell reduction. Vascular endothelial growth factor (VEGF) and fibroblast growth 
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factor -2 are crucial factors in the process of angiogenesis. Thus, targeting therapies to 
inhibit angiogenesis can aid in preventing cancer metastases (Cross 2001). Gurunathan 
and coworkers investigated the potential of AgNPs (diameter: 50nm) to inhibit cell 
proliferation, migration and capillary-like tube formation induced by VEGF in bovine 
retinal endothelial cells (BRECs) (Gurunathan 2009; Kalishwaralal 2009). The authors 
further proved that heparin-derivatized polysaccharide-reduced AuNPs and AgNPs 
exhibited similar FGF-2 induced anti-angiogenesis. The anti-angiogenic property of 
AgNPs is attributed to inhibition of P13K/Akt signaling (Mukherjee 2005). 
 
Nallathamby and coworkers observed growth inhibition of mouse fibrosarcoma cells by 
AgNPs in a time and dose-dependent manner. They also observed that these 
nanoparticles caused segregation of chromosomes and thus assist in inhibiting tumor cell 
growth (Nallathamby 2010).  
 
AgNPs have also shown the ability to be used in conjunction with several therapies to 
bring about additive toxic effects. AgNPs, when used along with DOX, have shown 
deleterious effects on cellular DNA by changing DNA conformation and hence affecting 
viability in tumor cells (Hekmat 2012).  These nanoparticles have also shown radiation 
sensitizing effects in glioma cells (Xu 2009). AgNPs have also shown extensive in vivo 
applications in tumor models (Sukirthaa 2012; Lara-González 2013; Park 2013), and 
recent investigations have suggested that AgNPs have the potential for use as a 
photodynamic agent (Mfouo-Tynga 2014). Thus, AgNps hold great promise in being 
used as multifunctional drug delivery vehicles. 
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Many anticancer drugs (in free form or particles form) often target apoptosis (Fulda 
2006). Therefore, understanding their mechanisms in this process would help in 
understanding the response of therapies (alone or in combination) and also help in 
developing new strategies of therapies.  
1.2.3. Role of apoptosis proteins in evaluating treatment efficacy of PTT based 
treatments:  
Apoptosis is a natural cellular process to check uncontrolled cell proliferation. This term 
was first introduced by Kerr, Wyllie, and Currie in 1972; however the components of the 
process were discovered long before the coining of this term (Kerr 1972). This process 
has been widely accepted as a form of programmed cell death wherein, it is genetically 
determined to eliminate old and worn- out cells. It is a part of the cell homeostatic 
mechanism for maintaining cell populations in tissues. This is also an important defense 
mechanism, wherein, cells damaged by any disease or harmful external agents are 
eliminated (Norbury 2001).  
 
Although there are several external stimuli and conditions that can lead to apoptosis; cells 
need not be essentially triggered to cell death by the same stimuli. Therefore, at this 
juncture anti- apoptotic proteins play a major role in evading cell death. Therefore, 
enhanced expression of anti-apoptotic proteins and weak expression of pro-apoptotic 
proteins can lead to cancer cell survival (Hoeppner 2001).  
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The apoptosis process is carried out using three widely accepted mechanisms: extrinsic 
pathway, intrinsic pathway and the perforin pathway (Elmore 2007). Apoptosis 
mechanisms are energy- dependent and involve a cascade of molecular events. These 
pathways converge into cleavage of caspase-3 and further DNA fragmentation, 
cytoskeletal and nuclear proteins degradation, apoptotic body formation and uptake by 
phagocytotic cells (Martinvalet 2005).  
 
The extrinsic pathway involves death receptors which are members of tumor necrosis 
factor receptor (TNF) (Walczak 2000). These receptors transmit death signals from the 
cell surface to intracellular signaling events. The most widely studied death receptor is 
TNF- related apoptosis- inducing ligand- receptor 1 and 2 (TRAIL-1 and TRAIL-2). The 
intrinsic pathway involves outer mitochondrial membrane permeabilization by pro-
apoptotic proteins (Green 2004). Disruption of the mitochondrial membrane causes the 
release of pro-apoptotic proteins which trigger cell death by caspase-3 stimulation 
(Saelens 2004). The perforin based pathway is induced by cytotoxic T- cells, wherein 
caspase-10 activation finally stimulates caspase-3 expression (Martinvalet 2005).  
 
Cancer cells often resist these death pathways by an increased expression of anti- 
apoptotic proteins or by a decrease or defective function in pro-apoptotic proteins, or 
mutations of genes regulating the mitochondrial pathway (Fulda 2006). Pro-apoptotic 
proteins (such as caspase-3) thus aid in cell death, and anti-apoptotic proteins (such as 
HSP70) aid in cell survival. The ratio of expression of both determines the fate of a cell. 
A defective apoptosis process involves either defective or less expressing pro-apoptotic 
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proteins and/or increased expression of anti-apoptotic proteins. Since, most of the cancer 
therapeutics target apoptosis mechanisms; such defects can affect their treatment 
efficacy. Thus, understanding the expression kinetics of these proteins and the 
development of sensors to measure their levels in real time can help in the evaluation of 
the efficacy of treatment modalities associated with this process. Measurement of high 
levels of HSP70 and low levels of caspase-3 would denote reduced efficacy and on the 
other hand, reduced expression of HSP70 and increased expression of caspase-3 would 
denote enhanced efficacy of a treatment modality.  
 
1.2.3.1 Heat shock proteins in PTT treatment: 
 
Heat shock protein 70 (HSP70) is one of the classes of heat shock proteins which are 
preferentially expressed in tumors. HSP70 levels are elevated in several tumors and their 
overexpression often denotes a poor prognosis in terms of response to therapy (Cornford 
2000). Elevated expression of these proteins denotes spontaneous protection from 
malignancy and also therapy. Thus, HSP70 expression is a major obstacle in rendering 
effective treatment (Volloch 1999). For tumor cell survival, correct conformation and 
function of cellular proteins is necessary. Thus, these HSP70 proteins exert their anti-
apoptotic role by inhibiting key check points of apoptotic machinery and help unfold 
denatured proteins inside the cell on exposure to stress, such as heat or chemotherapeutic 
agents (Arya 2007).  
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Anticancer therapy often involves denaturation of proteins. Chemotherapeutic agents 
have often been shown to have detrimental effects on proteins. Doxorubicin (DOX) 
commonly exerts its anti- tumor activity by DNA damage. Mandili et al, (2012) described 
a different mechanism of action of Doxorubicin. It was found to cause: i) dose- 
dependent over-ubiquitylation of proteins in the absence of proteosome, (ii) deplete 
activity of ubiquitylated enzymes and (iii) enhance binding of HSP70 with ubiquitinated 
proteins. Thus, silencing of these proteins can enhance the apoptotic effect of DOX 
(Mandili 2012). Hyperthermia- based cell killing, where temperatures are greater than 
40°C causes protein denaturation (Day 2009). HSP70 is often tailored to be released only 
under stress and its main signal is the presence of denatured cellular proteins (Voellmy 
2004). Cancer cells gain thermotolerance upon prolonged heating at a sub-lethal level. 
Induction of thermotolerance in pre-heat treatment also confers drug resistance to cancer 
cells. Thus, an elevated response of HSP70 in cancer cells is associated with resistance to 
both chemotherapy and hyperthermia, and hence measurements of HSP70 levels can 
indicate resistance to the combinatorial therapy of chemotherapy and hyperthermia. 
Therefore, measurement of low levels of expression of this protein implies higher chemo-
hyperthermia treatment efficacy.  
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1.2.3.2 Caspase-3 proteins in PTT treatment:  
 
Caspase-3 (or apopain) belongs to the family of cysteine proteases, and is a major pro-
apototic protein. Death signals generated through several stimuli converge into a common 
pathway involving caspase-3 as the primary signaling protein, as described in the 
previous section 2.3 (Martin 1995). It is produced inside the cells in an inactive form 
(pro-caspase). This inactive form is further stimulated to active apoptotic proteins by 
means of a death- inducing stimulus by cancer therapy (Hasegawa 2001). Most of the 
chemotherapeutic drugs exert their anti-apoptotic activity through the intrinsic pathway 
leading to caspase-3 expression. Thus, caspase-3 is the major pro-apoptotic signal in 
cancer cells undergoing chemotherapy (Fulda 2006). Chemotherapeutic agents also cause 
protein denaturation and DNA damage; therein caspase-3 plays a major role a protease 
(Kaufmann 2000). Hyperthermia- based cell killing is also associated with expression of 
caspase-3 (Hermisson 2000). Thus, enhanced expression of caspase-3 has been associated 
with an enhanced apoptotic effect in both chemotherapy and hyperthermia. Its expression 
can be used to evaluate treatment efficacy of the combination of both chemotherapy and 
hyperthermia. Enhanced expression of caspase-3 would suggest enhanced therapeutic 
efficacy of chemo-hyperthermia treatment.  
 
1.2.4. Role of intracellular redox environment in evaluating treatment efficacy: 
 
Tumor cells possess an altered redox environment as well as an increased rate of 
production of reactive oxygen species (ROS) in comparison to normal cells. Redox 
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production and elimination rates are both much higher than those in normal cells. Thus, 
tumor cells are more dependent on ROS scavenging capacity. b) The dependence of 
cancer cells on their antioxidant potential can be exploited in anticancer therapies in order 
to selectively target tumor cells without affecting normal cells.  c) Application of 
antioxidant inhibitors can impair ROS scavenging capacity in cancer cells, resulting in 
ROS overload which in turn causes a cytotoxic effect. d) Normal cells are also affected 
by a small overburden of ROS, but do not lose their cellular homeostasis. Cancer cells, on 
the other hand, can be easily affected even with a small overload of ROS, subsequently 
losing cellular homeostasis and dying from oxidative stress. (Figure adapted from 
(Glasauer 2014))  
 
The following two sections will discuss the ways to modulate ROS levels to treat cancer. 
 
1.2.4.1. Role of reactive oxygen species in PDT-based combinatorial therapy: 
Chemotherapeutic drugs and ionizing radiation are known to mediate their cytotoxic 
effect through promotion of intracellular ROS production, thus causing irreversible 
oxidative damage to cells (Wondrak 2009). Drugs such as taxol and several anti-folates 
promote mitochondrial-based cell death by disrupting their electron transport capacity, 
thereby increasing intracellular ROS production (Kaufmann 2000). Other drugs such as 
cisplatin and DOX also mediate their anti-tumorigenic activity through elevated 
production of ROS (Conklin 2004). ROS-producing monoclonal antibodies such as 
rituximab have also been synthesized for targeted treatment of non-Hodgkin’s lymphoma 
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(Renschler 2004). Elesclomol (STA-4783) is a ROS-producing compound in clinical 
trials for treatment of malignant melanoma cells.  This formulation has been shown to 
increase tumor progression-free survival when applied as a single agent, and significantly 
increased antitumor effect upon administration with paclitaxel. Its mechanism of action is 
still under investigation, although treatment effectiveness was reduced several fold when 
antioxidants were administered simultaneously (Kirshner 2008). The most common 
problem encountered with these drugs is their selectivity to tumors. However, a more 
targeted ROS-producing drug can effectively induce tumor cell apoptosis. Several 
researchers have suggested that AgNPs and silver nanocomposites affect cellular viability 
through production of ROS (Arora 2008; Hsin 2008). 
 
1.2.4.2. Role of anti-oxidants in PDT based combinatorial therapy: 
 
A major drawback of anticancer therapies associated with elevated production of ROS is 
the development of resistance to elevated ROS. Tumor cells produce endogenously 
elevated levels of anti-oxidants that help detoxify and scavenge the ROS produced 
(Lenehan 1995. ). Oncogene-induced tumors generate elevated levels of antioxidant need 
to define proteins such as NRF2 (Taguchi 2011). Glutathione (GSH) is a major 
antioxidant produced in elevated levels in tumor cells. GSH protects tumor cells from cell 
death and also prevents apoptosis in ROS-inducing therapies such as chemotherapies (Tai 
2012). Thus, disabling the anti-oxidant potential of tumor cells triggers ROS-mediated 
cell death in numerous tumor cell types (Trachootham 2006; Glasauer 2014). 
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Phenethyl isothiocyanate (PEITC) interacts with intracellular GSH through electrophile-
nucleophile interactions, depleting the GSH pool and leading to oxidative stress-mediated 
cell death. PEITC can cause cell death in HRAS(V12) transformed ovarian cancer cells 
and also prolong survival in an ovarian cancer xenograft model (Trachootham 2006). L-
Bethionine-sulfoximine (BSO) depletes intracellular GSH and has also shown synergistic 
anticancer effects with cisplatin in preclinical studies (Bailey 1997; Engel 2006). AgNPs 
have been shown to cause their anti-cancer effect through large reductions in intracellular 
thiol concentration, especially GSH (Nguyen 2013). The plant-derived compound 
Piperlongumine (PL) increases intracellular ROS by modifying the expression of the 
antioxidant enzyme glutathione transferase, thus modifying the ROS-stress response. 
This compound exerts an anticancer effect in breast, bladder and lung cancer models and 
their respective mouse models (Raj 2011). Thioredoxin is another intracellular thiol-
based antioxidant which is overexpressed in many cancers. Several inhibitors of 
thioredoxin have been created and investigated to show anti-tumor activity in vivo, such 
as PX-12 (Welsh 2003), Motexafin gadolinium (Magda 2006), etc.  The antioxidant 
regulator gene NRF2 has been widely investigated as a potential target for anticancer 
therapy. NRF2 inhibition can reduce the antioxidant system and induce ROS-mediated 
cell death in tumor cells (Satoh 2013). 
 
The success of combined therapies depends on a thorough understanding of the 
mechanisms behind cellular responses to cytotoxic agents. The goal of my study is to 
generate two different multifunctional nanoparticles to explore their cellular responses 
and how they are mediated by agent-specific mechanisms. One type of nanoparticle 
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requires the simultaneous release of two drugs, and the effect of the nanoparticles on 
cellular systems upon exposure to two heat treatment modalities would be explained by 
apoptotic and anti-apoptotic protein expression kinetics. In the other type of nanoparticle, 
the nanoparticle itself is a drug molecule which would act via reactive oxygen species 
generation and intracellular thiol reduction. In the latter type of formulation, one of the 
therapeutic agents is actually the framework for the nanoparticle construct. Thus, once 
the particles reach a target site, the cytotoxic agent can be immediately activated, and the 
particle can release its cargo.    
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CHAPTER 2: STATEMENT OF PURPOSE AND SPECIFIC AIMS 
2.1. Statement of Purpose:  
The overarching goal of this dissertation was to prepare multifunctional nanoparticles for 
combined theranostics, as well as to understand the different mechanisms and effects that 
derive from utilization of different multifunctional designs. We also evaluated drug 
delivery strategies with different co-therapy types, by designing two nanoparticle 
formulations that both contained DOX as a chemotherapy agent, but varied in the form of 
co-therapy utilized. In one formulation, we design a nanoparticle system for combined 
chemotherapy and photothermal therapy, whereas in another formulation we used a 
nanoparticle system for combined chemotherapy and photodynamic therapy. 
For combined chemotherapy-photothermal therapy, we performed simultaneous 
incorporation of a near-infrared activatable agent (i.e. an agent that can be activated using 
NIR light for hyperthermia or photodynamic activity) and a chemotherapeutic agent into 
polymeric PLGA nanoparticles for combined chemo-laser based phototherapy. We chose 
ICG and DOX as the near-infrared agent and DOX as the chemotherapeutic drug. 
Further, we studied the cellular response to these nanoparticles upon exposure to two 
types of heat treatment: laser-ICG-based therapy and incubator hyperthermia. These two 
modes of hyperthermia emulate clinical localized and whole-body hyperthermia 
respectively. Photothermal therapy affects cellular proteins by disrupting their folding 
and/ or denaturing them. One of the major limitations of this therapy is the possible 
induction of thermal tolerance due to overexpression of heat shock protein 70, an anti-
apoptotic protein widely implicated in cellular resistance to treatment. Based on the 
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severity of the thermal insult, however, cells may later exhibit downregulation of heat 
shock protein 70, ultimately resulting in apoptosis or necrosis, depending on the degree 
of cellular damage. The cellular response of these nanoparticles was hence studied using 
HSP70 and Caspase-3 expression kinetics because the co-therapy is based on 
photothermal therapy. One of the limitations of these multifunctional nanoparticles is the 
need to exert careful control over the release of both agents in order to obtain the desired 
therapeutic effect.  
For combined chemotherapy-photodynamic therapy, we created multifunctional 
nanoparticles where the nanoparticle itself acts as a near-infrared light-activatable 
therapeutic agent (multifunctional AgNPs). This multifunctional nanoparticle system 
provides an advantageous design as the nanoparticle itself serves as a drug delivery 
vehicle and phototherapeutic agent. Photodynamic therapy affects the redox state of the 
cells. Thus, the application of photodynamic therapy or co-therapy involving 
photodynamic therapy will result in enhanced generation of reactive oxygen species 
along with reduction of the antioxidant potential of the cell. Therefore, we studied the 
cellular response to these multifunctional silver nanoparticles based on intracellular 
generation of reactive oxygen species and reduction of thiol and glutathione levels, as 
thiol and glutathione are part of the cell’s antioxidant response system. 
 
2.2. Specific Aims: 
The specific aims corresponding to this research were: 
Specific Aim#1:  
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a) Prepare and characterize polymeric polyester nanoparticles (i.e., Poly-lactide-co-
glycolide or PLGA) with simultaneous incorporation of indocyanine green and 
doxorubicin (designated as IDNP) and surface decorate with an antibody against human-
epithelial receptor-2 (HER-2) (designated as AIDNP). PLGA was chosen because it is an 
FDA-approved copolymer widely used for drug delivery applications, whose properties 
can be easily engineered to simultaneously entrap both hydrophilic (ICG) and 
hydrophobic (DOX) agents. The surface properties of the polymer can also be easily 
modified to attach ligands for cell-specific receptors to achieve active targeting.  
b) Evaluate the in vitro cytotoxic effect, cellular uptake, and drug release kinetics of 
the IDNPs and AIDNPs. 
Specific Aim #2: 
Evaluate HSP70 and caspase-3 expression from cell lysates after exposure to incubator 
hyperthermia and DOX, free DOX+ICG hyperthermia, IDNP hyperthermia and AIDNP 
hyperthermia, using ELISA based measurements to evaluate time expression of HSP70 in 
cancer cells MES-SA, MES-SA/DX5 and SKOV-3. 
Specific Aim# 3: 
a) Prepare and characterize AgNPs which are decorated with the folic acid (FA) 
targeting ligand via an amide bond, a chemotherapeutic drug doxorubicin (DOX) is 
conjugated to AgNPs via an acid-cleavable hydrazone bond and a polyethylene glycol 
(PEG) spacer.  
b) Evaluate pH-triggered release of the drug (DOX) by Surface-Enhanced Raman 
Spectroscopy and Fluorescence Microscopy.  
68 
 
c) Evaluate the ability of AgNPs to act as a photodynamic agent upon laser 
irradiation in vitro.  
d) Evaluate the uptake and cytotoxity of this silver nanoparticle carrier system in 
cancer cells (MES-SA, MES-SA/DX5 and SKOV-3) to show the combined 
chemotherapeutic-photodynamic effect.  
e) Evaluate cellular response to these nanoparticles by measuring intracellular 
generation of reactive oxygen species (ROS) and reduction of thiol and glutathione. 
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CHAPTER 3:  COMBINED PHOTOTHERMAL THERAPY AND CHEMOTHERAPY 
IN CANCER USING HER-2 TARGETED PLGA NANOPARTICLES – AN IN VITRO 
STUDY 
This chapter is based on my work completed and published in the article: Srinivasan, S.; 
Manchanda, R.; Lei, T. J.; Nagesetti, A.; Fernandez-Fernandez, A.; McGoron, A. J. 
Targeted nanoparticles for simultaneous delivery of chemotherapeutic and hyperthermia 
agents-An in vitro study. J. Photochem. Photobiol. B, 2014, 136, 81–90. Permission has 
been obtained from the journal editors to use the information and data from this article 
in my dissertation manuscript, and a copy of this permission has been included in the 
appendices. 
3.1. Background 
Cancer is one of the primary causes of death in the developed world, second only to 
cardiovascular disease. The main challenges in battling cancer include both the capability 
to detect it as early as possible, and the ability to treat it in a specific and effective way. 
As a result, the centerpiece of current cancer research involves the development of 
improved detection and treatment strategies that can better equip the medical team in 
dealing with the disease. Current cancer therapies include chemotherapy, radiotherapy, 
immunotherapy, and hormone therapy, among others. A common management approach 
that results in improved clinical outcomes is combinational therapy, i.e., the co-
administration of several anticancer agents or modalities. In this case, two or more 
therapeutic agents or different therapies such as chemotherapy, hormone therapy, 
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immunotherapy, and radiotherapy, are simultaneously used in order to try to maximize 
the treatment effect on cancer tissue. The use of combinational therapy also helps 
decrease off-target and dose-dependent toxicities, as it allows a reduction in the overall 
drug dose given to the patient (Liotta L 2000). This is also an important consideration in 
achieving optimal clinical outcomes. 
Doxorubicin (DOX), also known as Adriamycin, is a common anticancer drug which has 
been used for decades based on its effectiveness against a wide spectrum of neoplasms. 
DOX exerts its cytotoxic action through two mechanisms: (1) generation of free radicals 
and (2) DNA intercalation in the nucleus, with the latter being the most predominant 
mechanism of cytotoxicity in tumor cells. Despite its effectiveness in reducing the 
viability of cancer cells, DOX is clinically limited by its lack of tumor specificity, dose-
dependent cardiotoxicity, and the development of multidrug resistance which hampers 
the long-term efficacy of the treatment (Sinha 1990).  
A possible approach to overcoming the dose-related limitations of chemotherapy agents 
is to use combinational therapies such as simultaneous hyperthermia and chemotherapy 
in order to obtain more efficacious treatment of cancer with reduced doses of 
chemotherapy. Cancer cells can be selectively killed by hyperthermia in a range of 
temperatures that are relatively innocuous to healthy cells (41- 43 oC) (Cavaliere R 1967). 
Additionally, hyperthermia can result in increased membrane permeability which can in 
turn create increased sensitivity of cancer cells to other cytotoxic agents (Christophi C 
1998). Hyperthermia mediated by near-infrared absorbing agents and triggered by laser 
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exposure also has the advantage of providing non-invasive treatment with greater tissue 
penetration of light compared to visible light (Ntziachristos V 2003). Indocyanine Green 
(ICG) is a near-infrared absorbing dye widely used in clinical applications such as 
cardiac output measurement and ophthalmic angiography (Benya R 1989). It can also be 
used as an agent for localized hyperthermia treatment (Chen 1996; Lucroy 2002). 
However, the application of ICG for in vivo hyperthermia is limited by its rapid plasma 
clearance and rapid degradation in an aqueous environment (Saxena 2003). 
Some of the concerns that arise from the non-specificity of cancer therapeutics can be 
reduced through the use of nanoformulations. Nanomedicine is a relatively new, yet 
rapidly progressing area in the field of cancer therapy, which offers great potential in 
combining multiple therapeutic modalities and functionalities into a single platform. 
Combinational cancer therapy using nanoformulations of inorganic materials such as gold 
or iron, carbon nanotubes, and polymers is being increasingly explored (Fernandez-
Fernandez 2011). In drug delivery applications, degradable polymeric biomaterials (both 
synthetic and natural) are preferred because their biodegradation can be easily 
manipulated for efficient and controlled drug release (Nair LS and Laurencin CT 2007). 
Poly lactide co-glycolide (PLGA) is a biocompatible polymer approved by the Food and 
Drug Administration for use as a drug delivery vehicle in humans. One of the advantages 
of PLGA in drug delivery is the fact that its degradation products, lactic acid and glycolic 
acid, are easily metabolized by the body. This, along with the ability to manipulate the 
copolymer ratio and polymer weight for controlled drug release, makes PLGA the most 
widely investigated polymer for drug delivery (Danhier F 2012). 
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Nanoparticles offer the possibility of increasing the specificity of drug delivery through 
both passive and active targeting. Because tumor tissues have leaky vasculature with 
pore sizes ranging anywhere from 100-780 nm, drug-loaded nanoparticles tend to 
accumulate preferentially in tumor tissues as compared to healthy tissues, although the 
degree of passive targeting can vary widely because of differences in tumor vasculature 
and the variability of its porosity depending on tumor type and staging (Hobbs 1998; 
Brigger 2002). Active targeting can overcome this concern by specifically directing 
nanoparticles for uptake into tissues which express the corresponding receptors, based 
on the decoration of nanoparticle surfaces with tumor-selective ligands. Many different 
ligands have been reported in targeted delivery applications, including monoclonal 
antibodies, peptides, and carbohydrates. Monoclonal antibodies in particular have 
excellent tumor targeting capabilities due to their high specificity to tumor markers. 
Several studies have used HER-2 (Human Epithelial Receptor-2) for targeting, as 
overexpression of HER-2 on tumor surfaces has often been correlated with poorer 
prognostic indicators including angiogenesis, metastasis and resistance against 
apoptosis-inducing therapeutic agents (Nair 2005). HER-2 is over expressed in 20-25% 
of ovarian cancers (Vermeij J 2008). Targeted therapy is achieved using receptors that 
have high copy numbers on cancer cells with respect to normal cells (105-106 
receptors/cancer cell which is 100 fold higher than that in normal cell) (Kurebayashi J 
2001). 
Our group previously reported the simultaneous entrapment of ICG and DOX into 
PLGA nanoparticles for combined imaging and therapy (Tang 2010). This chapter 
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discusses further development of these agents to incorporate active targeting by surface 
conjugation with monoclonal antibodies against HER-2; and the potential of this 
targeted formulation for combined chemotherapy, hyperthermia and imaging in cancer 
cells with different drug resistance mechanisms.  
3.2. Methods 
3.2.1. Drugs and Chemicals: 
Poly (DL-lactide-co-glycolide) (PLGA, L: G: 50:50; MW: 40,000–75,000; Tg: 45°C–
50°C), doxorubicin hydrochloride (MW: 579.95), dimethylsulfoxide (DMSO>99.9% 
reagent grade), and polyvinyl alcohol (PVA, 87–89% hydrolyzed; 13KDa-23KDa) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Indocyanine Green was 
purchased from Acros Organics. Dichloromethane (DCM) was purchased from Burdick 
& Jackson (Muskegon, MI, USA).  
3.2.2. Synthesis of IDNPs: 
PLGA nanoparticles with dual incorporation of ICG and DOX (IDNP) were prepared 
using an oil-in-water emulsion solvent evaporation technique (Manchanda 2009). The 
protocol was previously optimized for maximum drug entrapment. Briefly, 60 mg of 
PLGA, 1 mg of ICG, and 1 mg of DOX were dissolved in 4 ml of methanol-
dichloromethane (1:3 v/v) mixture. The organic phase was emulsified with 8 ml of PVA 
solution (3%, w/v) by sonication at 50 W for 1 min in an ice bath. The organic solvent 
was then removed under reduced pressure at 39 °C. The nanoparticle suspension was 
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centrifuged at 14,000 rpm (16,000 xg) for 30 min. The precipitate was further washed 
with equal volumes of distilled water and centrifuged again. The nanoparticle precipitate 
was freeze-dried and lyophilized. 
3.2.3. Antibody conjugation to IDNPs to prepare AIDNPs: 
The IDNPs were conjugated with anti-HER-2 using a modified protocol reported by 
Yang et al (Yang 2007). Briefly, the lyophilized IDNPs were resuspended in PBS (0.1 
M, pH 7.4, 1 mg/mL). 1 mL of 2.0 mM NHS and 2.0 mM of EDC was added to the NPs 
and left to react for 20 min. Then, the activated NPs were reacted with 50 µL (100 µg) 
of IgG antibody for 1 hr. The NPs (AIDNP) were recovered by centrifugation at 12,200 
rpm (13943 xg), 6°C for 30 minutes. The pellets were washed and resuspended in PBS 
(0.1 M, pH 7.4, equal volume of supernatant). The particles were then freeze-dried and 
lyophilized. 
 
3.2.4. Characterization of NPs: 
 
The size and size distribution of IDNPs and AIDNPs were measured by dynamic light 
scattering (DLS) with a Malvern Zetasizer (Malvern Instruments, Worcestershire, 
United Kingdom) at 25°C, using a 1:30 (v/v) dilution of the NP suspension in distilled 
water. The same instrument was used to measure the zeta potential of the NPs dispersed 
in deionized (DI) water.  
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3.2.5. Dye loading into NPs: 
 
The concentrations of ICG and DOX encapsulated in the NPs (both IDNPs and 
AIDNPs) were determined using a Fluorolog-3 spectrofluorometer (HORIBA Jobin 
Yvon Inc., USA) in steady-state mode. Drug entrapment was measured after dissolving 
the NPs in DMSO, as previously reported by our group (Manchanda 2009). Briefly, 
serial dilutions of the supernatant were done in order to reach the linear range. Then, the 
maximum peak intensities of the supernatant solution were blank corrected and used to 
fit to a linear model for drug loading estimation. 
 
3.2.6. Antibody conjugation efficiency estimation: 
 
The amount of antibody conjugated per nanoparticle (antibody conjugation efficiency) 
was measured using a modified protocol reported by Mo and Lim (Mo 2005).  1 mg of 
lyophilized particles (AIDNP) was dissolved in 0.5 ml DMSO and 1 mL of 0.5% (wt. 
/vol.) Sodium dodecyl sulfate (SDS)/0.05M NaOH (salinated SDS) and incubated for 4 
hrs. One mL of this solution was mixed with an equal volume of Bicinchonic acid 
(BCA) reagent for 60 min at 60 °C. The absorbance of this mixture was estimated at 562 
nm using a spectrophotometer. The instrument was calibrated with standard bovine 
serum albumin protein solutions (0.5-40 µg/ml) in the same proportion of DMSO and 
salinated SDS solution. IDNPs were used as blank. Conjugation efficiency was 
expressed as weight of antibody (µg) per unit weight (mg) of nanoparticles. 
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3.2.7. In vitro studies of NPs: 
Human uterine sarcoma MES-SA cells, and their drug resistant counterpart (P-gp over-
expressing derivative) MES-SA/Dx5 (Dx5) cells, human ovarian carcinoma SKOV-3 
cancer cells, McCoy's 5A medium, and fetal bovine serum were purchased from 
American Type Culture Collection (Manassas, VA). Formalin, 24-well tissue culture 
plates and Poly-D-lysine coated coverslips were purchased from Fisher Scientific 
(Pittsburg, PA). Penicillin was purchased from Sigma-Aldrich. All cells were cultured in 
McCoy's 5A medium supplemented with 1% penicillin and 10% fetal bovine serum, and 
kept in a 37°C cell incubator with a humidified atmosphere of 5% CO2 and 95% air.  
 
3.2.8. In vitro drug release kinetics profile:  
AIDNP (5 mg) was resuspended in 3 ml of 0.01M PBS (pH = 7.4). This sample was 
divided into three centrifuge tubes. The tubes were shaken at 35 rpm, 37 oC in an 
incubator. These tubes were removed from the incubator at regular intervals and 
centrifuged at 14,000 rpm (16,000 xg), 30 min. The supernatants were collected for 
DOX estimation and the pellet was resuspended with fresh buffer. This process was 
repeated for each time point up to 48 hours. 
3.2.9. Subcellular localization of NPs: 
MES-SA, Dx5 and SKOV-3 cells (4 X 104) cells/well were seeded onto Poly D, L-lysine 
coated coverslips placed into 24-well culture plates, and the cells were incubated to 
reach confluence. After 24 hours incubation, the medium was replaced by medium 
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containing IDNP or AIDNP corresponding to equivalent ICG and DOX concentrations 
of 6.2 µM and 10 µM respectively. After 24 h incubation, the cells were washed 3X with 
DPBS to remove free drugs (IDNP or AIDNP) and then fixed with 4% 
paraformaldehyde solution for 20 min. The cells were further washed 3X with DPBS. 
The fixed cells were viewed under fluorescence microscope (Olympus IX81, Japan) and 
imaged under a water-emersion 60x objective at λex (480–490 nm), λem (≥515 nm) for 
the DOX window, and λex (775 nm), λem (845 nm) for the ICG window. The 
fluorescence signals were acquired using a CCD camera and merged using software to 
give a pseudo-color (IPLab, Qimaging, Canada). The settings of the microscope were 
kept constant throughout the experiment; however, different exposure times were used 
for the ICG and DOX windows to optimize the images. The fluorescence comparisons 
between IDNP and AIDNP were done within the same cell lines. 
 
3.2.10. Cellular uptake experiments:  
 
The cellular uptake of AIDNP and IDNP was quantified as follows. First, 2 X 104 cells 
were seeded in a 24 well tissue culture plate, and after the cells reached confluency, the 
cell medium was removed and IDNP and AIDNP resuspended in growth medium (with 
equivalent DOX and ICG concentrations as described in the previous section) for 24 hrs.  
Cells that were not subjected to any treatment were considered controls. After 24-hour 
incubation, the cells were washed with ice-cold DPBS (pH 7.4) and lysed using 1 ml 
DMSO. The cell lysis product was centrifuged at 14,000 rpm (16,000 xg) for 10 min to 
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remove cell debris. The fluorescence intensity of cell lysates was measured using a 
Fluorolog-3 (Jobin Yvon Horiba) spectrofluorometer at λex = 496 nm, λem = 592 nm for 
DOX in order to determine the uptake of IDNP and AIDNP by the cells. DOX 
calibration was previously created in a mixture of ICG-DOX dissolved in DMSO along 
with untreated cells. The protein content in the lysates was measured using a BCA assay 
kit. The uptake data was obtained by normalizing DOX content to the cellular protein 
level for three different experiments (three wells each for each treatment per cell line).  
A paired t-test was used to compare the 24-hr uptake of DOX between the treatments 
corresponding to the same equivalent concentration. 
 
3.2.11. Cytotoxicity and hyperthermia assessment: 
Cell viability after drug treatment was measured using a Sulforhodamine B (SRB) assay 
(Invitrogen, Carlsbad, CA, USA), which measures cellular protein (Monks A 1991). In 
this study, AIDNP and IDNP (equivalent to 0.1, 1 and 10 µM DOX) were incubated 
with MES-SA, Dx5 and SKOV-3 cells for 24 h to evaluate their toxicity. The detailed 
procedure for toxicity assessment has already been discussed in our previous report 
(Tang 2009). Average absorbance value was measured from four wells corresponding to 
the same treatment and cell line. An average (±S.D.) was determined from three 
independent experiments and was plotted against the respective DOX concentration. 
Cell growth fractions were determined by normalizing the data corresponding to 
treatment to control.  
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The methods for delivering hyperthermia and measuring its synergistic effect with DOX 
have also been published previously (Tang 2009). ICG at a dose of 5 µM during 3-min 
exposure to an 808-nm laser at energy density of 1,440 J/cm2 (6.7 W/ cm2, power 
density) increases the temperature of incubated cells from a baseline of 37 oC to 43 oC 
for selective hyperthermia. In this study, the cytotoxicity of four different treatments 
(IDNP w/o laser treatment, AIDNP w/o laser treatment, IDNP w/ laser treatment and 
AIDNP w/ laser treatment) were investigated. Cells were seeded into a 96-well plate on 
the first day, and after overnight incubation they were exposed to different treatments 
(each corresponding to equivalent DOX concentration of 10 µM and ICG concentration 
of 6.2 µM). The cytotoxicity was measured with the SRB assay 24 h post treatment in 
each case.  Average cell growth fractions were obtained from four wells for each 
treatment (n=3). The data were acquired and represented in the same manner as the 
toxicity of the formulations discussed in the previous paragraph. 
 
3.2.12. Statistical significance:  
Statistical significance was identified by one-way ANOVA (SPSS, Chicago, IL, USA) 
for the difference among treatment groups at the same DOX concentration. A p-value 
<0.05 was considered to be statistically significant. 
 
3.3. Results and Discussion 
3.3.1. Characterization of NPs  
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Size, size distribution, zeta potential and drug loading:  
The size and size distribution, charge and drug loading of non-targeted ICG and DOX 
loaded PLGA nanoparticles (IDNP) and anti-HER-2 targeted ICG and DOX PLGA 
nanoparticles (AIDNP) are listed in Table 1.  
This shows that IDNP exhibited a size of 167 ± 5 nm with polydispersity of 0.06 ± 0.03. 
An increase in size and size distribution of IDNP is observed after antibody conjugation. 
Similar results were observed in several studies (Mo 2005; Yang 2007; Lei 2010). IDNP 
and AIDNP both have the potential to accumulate in tumors due to passive targeting, 
however, AIDNP could further enhance drug accumulation inside tumor cells through 
enhanced internalization (Kirpotin 2006; Lei 2010). Because anti-HER-2 has an 
isoelectric point (pI) around 8.5, it has a positive charge at pH 7 (Barua S 2013) which 
masks the negative charge of the IDNP, creating a reduced nanoparticle surface charge. 
After antibody conjugation, the drug loading efficiency of IDNP is significantly reduced 
(p< 0.05) because of drug leaching during the conjugation process. This observation is 
consistent with literature reports (Mo 2005; Chittasupho 2009; Lei 2010). 
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Table 1. Mean size, PDI, zeta potential, percent drug loading and antibody conjugation efficiency for 
IDNPs and AIDNPs (n =3). 
 
3.3.2 In vitro release kinetics profile: 
Cumulative percentage of DOX released from AIDNPs is shown in Figure 2.  
Approximately 41 ±2.2% DOX is released in 8 hours, reaching a sustained release of 48 
± 2% in 48 hrs. This release kinetic profile is similar to that of IDNP previously reported 
by our group (Manchanda 2009), as well as to the biphasic DOX release profile reported 
by Zheng et al. from lipid-PLGA nanoparticles, which showed 39.13 % DOX release by 
8 hours. 
 Size (nm) PDI Zeta potential 
(mV) 
Loading % 
(w/w) 
Antibody 
conjugation 
efficiency 
(μg per mg 
nanoparticles)
IDNP 167 ± 5 0.06 ± 0.03 -11.3 ± 1.6 1.79 ±0.02 % 
ICG 
 
2.32 ±0.01% 
DOX 
AIDNP 210 ± 7 0.16 ± 0.01 -1.0 ± 0.5 1.39 ±0.01% 
ICG 
8.99±0.66 
1.91 ± 0.02 
% 
DOX 
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Figure 2. DOX release kinetic profile of AIDNPs. (error bars denote a mean and SD of n=3 experiments) 
 
The slow sustained release of DOX from targeted AIDNP and the biphasic behavior of 
the release profile observed in both AIDNP and IDNP are consistent with other literature 
reports as well (Yang 2007; Chittasupho 2009; Lei 2010).  The two phases of DOX 
release correspond to an initial burst release, followed by a sustained slow release. The 
first phase results from the release of drug that was adsorbed onto nanoparticle surfaces 
during formulation, whereas the second phase is due to nanoparticle degradation and 
drug diffusion from within the polymer carrier. In our nanoparticles, the high molecular 
weight and hydrophobicity of PLGA result in a slow release of the drug from the 
polymer. Polymers with higher molecular weight undergo slower degradation in 
comparison to lower molecular weight polymers, because a longer chain of interlinked 
monomers takes longer to degrade once sequestered in acidic cellular compartments 
83 
 
such as lysosomes. The hydrophobicity of PLGA can be easily tuned by changing the 
ratio of lactic acid to glycolic acid. High hydrophobicity of the polymer results in higher 
DOX-polymer interactions, which slows down the release of drug from the carrier. 
Additionally, high polymer hydrophobicity also results in lower water absorption and 
slower degradation and drug release (Dinarvand 2011). 
3.3.3. Antibody conjugation efficiency: 
The antibody conjugation efficiency of AIDNP was measured to be 8.90 ± 0.66 µg 
antibodies per milligram of NPs, which is consistent with literature reports (Kocbek 
2007; Lei 2010). 
 
3.3.4. Cell culture studies   
3.3.4.1. Subcellular localization studies 
Figures 3, 4, and 5 show fluorescence microscopy images which illustrate the sub 
cellular localization of IDNP and AIDNP in SKOV-3, MES-SA and Dx5 cell lines, 
respectively. The image exposure times were kept constant for each drug in the 
respective cell line for comparison purposes, and concentrations of IDNP and AIDNP 
used were, as previously described, determined by their corresponding equivalent ICG 
and DOX concentrations. The qualitative results show that AIDNP exhibited higher 
fluorescence for DOX and ICG in SKOV-3, when compared to the non-targeted 
formulation. AIDNP and IDNP showed similar fluorescence in both MES-SA and MES-
SA/Dx5 cells. 
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Figure 3. Subcellular localization of DOX and ICG in SKOV-3 cells; 24 hours post-incubation; the 
exposure time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of 
IDNP; b ICG fluorescence of IDNP; c merged picture of a & b; d DOX fluorescence of AIDNPs; e ICG 
fluorescence of AIDNPs; f merged picture of d & e. 
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Figure 4. Subcellular localization of DOX and ICG in MES-SA cells; 24 hours post-incubation; the 
exposure time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of 
IDNP; b ICG fluorescence of IDNP; c merged picture of a & b; d DOX fluorescence of AIDNPs; e ICG 
fluorescence of AIDNPs; f merged picture of d & e. 
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Figure 5. Subcellular localization of DOX and ICG in Dx5 cells; 24 hours post-incubation; the exposure 
time for DOX and ICG channel were 500 ms and 2000 ms respectively. a. DOX fluorescence of IDNP; b. 
ICG fluorescence of IDNP; c. merged picture of a. & b.; d. DOX fluorescence of AIDNPs; e. ICG 
fluorescence of AIDNPs; f. merged picture of d. & e. 
This is consistent with our expectations for increased uptake in SKOV-3 cells, given that 
this cell line over expresses HER-2 receptors (approximately 105 receptor/cell) (Xu 
1999).  Thus, high internalization rate of the receptor along with high specificity of the 
antibody to the receptor explains the higher uptake of AIDNP compared to IDNP in 
SKOV3 cells (Rudnick S 2011). MES-SA and Dx5 cells, used as negative control cells, 
do not over express the receptor and as a result we do not see any differences in 
fluorescence intensity between the IDNP and AIDNP groups.   
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IDNP and AIDNP exhibited similar intracellular localization in all three cell lines, and 
this localization was consistent with previous literature reports which have established 
that PLGA nanoparticles are internalized through endocytosis (Lei 2010; Tang 2010). 
The intracellular release of DOX from PLGA nanoparticles is due to hydrolysis of ester 
bonds in the PLGA polymer and to the increased solubility of DOX in mildly acidic 
intercellular components such as lysosomes (Tewes F 2007). Whereas DOX 
fluorescence in the cytoplasm might be the combined result of the internalized drug-
entrapped nanoparticles as well as drug released from the nanoparticles, DOX 
fluorescence in the nucleus must be from drug released from the nanoparticles, given 
that nanoparticles cannot enter the nuclear pores due to size limitations (Tang 2010). 
3.3.4.2. Cellular uptake experiments: 
The 24 h uptake of IDNP and AIDNP in MES-SA, Dx5, and SKOV-3 cells was 
quantified by measuring the DOX fluorescence in cells normalized to cellular protein 
content.  
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Figure 6. 24-hour intracellular DOX uptake data in SKOV-3, MES-SA, and Dx5 cells, n = 3 experiments, 
3 wells per treatment. * P < 0.05 (by ANOVA) between free drug and NPs formulation for each cell line, 
indicating significant differences due to loading of DOX into PLGA NPs. 
Figure 6 shows that AIDNP significantly enhanced DOX uptake in SKOV-3 cells in 
comparison to IDNP, with an approximate two- fold increase in the uptake of AIDNP in 
SKOV-3 in comparison to IDNP. This can be attributed to HER-2 receptor mediated 
endocytosis in SKOV3 cells, given that AIDNP and IDNP exhibited similar uptake in 
the negative control cell lines MES-SA and Dx5. These results are consistent with our 
previous report and other group reports on targeted drug delivery PLGA nanoparticle 
systems (Mo 2005; Lei 2010).  The zeta potential results of IDNP showed that they are 
negatively charged (-11 mV). Harush-Frenkel et al. reported that negatively charged 
PLGA nanoparticles are taken up by cancer cells through adsorptive endocytosis 
(Harush-Frenkel, Debotton et al. 2007). Receptor mediated endocytosis, however, is 
more efficient and specific in comparison to adsorptive endocytosis (Ogris M 2001). 
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The involvement of efficient receptor-mediated endocytosis is likely to be the 
mechanism that contributes to the higher uptake of AIDNP compared to IDNP in 
SKOV3 (HER-2 positive cell line).  
3.3.4.3. Cytotoxicity and effect of hyperthermia experiments: 
PLGA is a widely used polymer approved by the FDA for various applications (Danhier 
F 2012). Our previous reports have suggested that PLGA nanoparticles do not have toxic 
effects in the tested cancer cell lines up to 1 mg/ml, which is much higher than the 
concentration used for toxicity and uptake experiments (Vasir JK and Labhasetwar V 
2005). This is consistent with the safety profile of PLGA nanoparticles reported by Liu 
et al. (1.02 ± 0.37 mg/ml) (Liu 2012).  
Our cytotoxicity studies showed a dose-dependent increase in cytotoxicity for both 
IDNP and AIDNP in all three cell lines (Figures 7, 8 and 9). A 10 µM concentration of 
DOX was chosen due to its clinical relevance (Coldwell 2008 ), and our previous reports 
have shown synergistic cancer cell killing using 10 µM DOX and 6.2 µM ICG based 
chemo-laser phototherapy (Tang 2009).   
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         Figure 7. SKOV-3 cell growth for different drug formulations (without laser hyperthermia), n=3 
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell 
lines. 
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         Figure 8. MES-SA cell growth for different drug formulations (without laser hyperthermia), n=3 
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell 
lines. 
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               Figure 9. Dx5 cell growth for different drug formulations (without laser  hyperthermia), n=3 
experiments, 4 wells per treatment. No statistical significance seen between treatment groups in all cell 
lines. 
 
The results of the present work show a small enhancement of cytotoxicity in SKOV-3 
cells (without laser treatment) when AIDNP was used compared to IDNP. The 
difference is likely due to enhanced uptake of the targeted formulation by receptor-
mediated endocytosis, although the difference in cytotoxicity did not reach statistical 
significance. These results are consistent with our previous report of comparable toxicity 
of antibody-conjugated DOX-loaded PLGA nanoparticles (ADNP) and DOX-loaded 
PLGA nanoparticles (DNP) (Lei 2010).  Chittasupho et al also reported similar results, 
wherein c-LABL peptide conjugated DOX loaded nanoparticles exhibited comparable 
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toxicity to the non-conjugated nanoparticles (Chittasupho 2009). The comparable 
toxicity of AIDNP and IDNP (without laser treatment) that we observed despite the 
difference in uptake could be due to the aggressive nature of SKOV-3 cell lines. These 
cells have genetic mutations in caspase-3 and in apoptotic protease factor 1 expression, 
which make them resistant to DOX and in general to varied environmental stresses 
(Sood 2004). (Wolf BB 2001). For example, SKOV-3 cells have also been reported to 
be inherently thermotolerant, which could be attributed to their p53 mediated drug 
resistance (Van de Broek 2011; Manchanda 2012). The genetic characteristics of 
SKOV-3 may counteract the potential effects of enhanced uptake of DOX through 
AIDNP (in the absence of laser treatment). Our previous work suggested that combined 
laser hyperthermia and chemotherapy delivered through PLGA nanoparticles (IDNP) 
has the ability to significantly reduce the cell viability of this aggressive cell line and can 
partially overcome its ability to withstand chemical and thermal insults (Tang 2010). 
This observation was also confirmed by the present work, as AIDNP showed 
significantly enhanced toxicity (three-fold toxicity levels) in SKOV-3 after laser 
exposure when compared to the same treatment with IDNP (Figure 10).  The negative 
controls (MES-SA and Dx5) exhibited comparable cytotoxicity after exposure to laser. 
These results are consistent with our expectations because these cells do not overexpress 
HER-2 receptors, and in turn this supports the theory that targeting ability and the 
resulting enhanced uptake are related to the large increase in therapeutic effect that was 
observed in SKOV-3 when a combinational approach was used. Thus, targeted PLGA 
nanoparticles with simultaneously entrapped ICG and DOX could selectively enhance 
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cell killing in SKOV-3 cells through enhanced uptake and combinational therapy, 
creating opportunities for efficacious treatments against this aggressive cell line. 
 
 Figure 10.  Cytotoxicity of IDNP and AIDNP when excited by NIR laser. n=3 experiments, 4 wells per 
treatment. The concentration of IDNP and AIDNP was around 0.25 mg/ml, which contains 10 μM DOX 
and 6.2 μM ICG.  = significant difference (p < 0.05) versus non-laser group, = significant 
difference (p < 0.05) between laser groups. 
 
IDNP and AIDNP exhibited similar toxicity in the negative control cells MES-SA and 
Dx5, and 3-min laser hyperthermia exposure to IDNP and AIDNP did not provide any 
advantage over the free drug forms (ICG and DOX) in either cell line. Because the main 
difference between the two formulations is related to targeting capability, and these cells 
do not over express HER-2, it was to be expected that IDNP or AIDNP after laser 
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treatment could not provide a competitive cell killing advantage over their free drug 
forms. Additionally, the results obtained in Dx5 cells are consistent with our previous 
report where IDNP with 3 min laser exposure did not enhance cell killing. Extended 
laser exposure of IDNP to 5 min, however, was able to significantly increase toxicity to 
Dx5 cells, indicating that longer exposures to hyperthermia which create higher thermal 
doses may be effective in treating these DOX-resistant cells (Tang 2010). Zheng et al. 
also conducted a study by incorporating ICG and DOX into lipid-PLGA (IDLPNP) 
nanoparticles to test their effect on the drug sensitive and drug resistant cancer cells lines 
MCF-7 and MCF-7/Adr respectively. They reported that combined photo-chemotherapy 
through IDLPNP (with equivalent drug concentrations of 5.5 µg/ml ICG, 6.0 µg/ml 
DOX) upon exposure to NIR laser with irradiance of 1.6 W/cm2 irradiance for 5 min 
resulted in only 5% cell growth inhibition of the MCF-7/Adr cells 72 hours after laser 
exposure (Zheng 2013).  
Multi-drug resistance (MDR) in cancer cells is exhibited through over expression of 
multi-drug resistance proteins (MRP1). The level of expression of these proteins (or 
transcripts for expression of this protein; i.e., mRNA) can be correlated to their degree 
of drug resistance (Loe DW 1996). MCF-7/Adr cells are a drug resistant variant of 
MCF-7 cells exhibiting 6,000 multi-resistant protein 1(MRP1) mRNA copies. Dx5 (the 
drug resistant variant of MES-SA cells) exhibited four times more MRP1 mRNA copies 
than MCF-7/ Adr cells (Yang 2002). Thus, Dx5 cells are expected to be more drug 
resistant than MCF-7/Adr cells. Kampinga et al. reported that combinatorial heat and 
drug administration causes damage to MDR proteins; thereby sensitizing the cells to the 
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effect of drugs (Kampinga HH 2006). Protein denaturation due to hyperthermia 
treatment is highly dependent on the thermal dose provided, and at least 5% protein 
denaturation is required to bring about detectable cell toxicity (Lepock JR 2003). The 
above reason suggests the requirement of a high thermal dose to bring about appreciable 
protein denaturation and hence higher cell killing, and is consistent with our 
observations in Dx5 which support an effect at longer treatment durations (and thus 
higher thermal doses). Franke et al. have described additional mechanisms of 
cytotoxicity through combined chemotherapy and hyperthermia in MDR cell lines. They 
reported that there was a reduced expression of MRP1 in cell membranes of MDR cells 
after the combinational treatment, and showed that the mechanism through which this 
phenomenon occurs is that hyperthermia impairs the translocation of MRP1 to the 
membrane through increased ROS production at the protein level (Franke K 2013). 
Therefore, there can be a complex interplay of different mechanisms which mediate 
toxicity during photo-chemotherapy treatment in MDR cell lines.  All the mechanisms 
however, depend on the thermal dose provided during combined chemo-phototherapy. 
Conclusions:  
AIDNP can specifically target cancer cells (SKOV-3) which over express the receptor 
corresponding to the conjugated ligand (anti- HER-2 monoclonal antibody). AIDNPs 
also show great promise for combinatorial treatment employing both chemotherapy and 
hyperthermia, as an enhanced killing effect can be obtained from combinational 
treatment using the targeted formulation.  In our next chapter, we will investigate the 
97 
 
effect of IDNP and AIDNP in combination with localized vs. generalized hyperthermia, 
in order to better understand the molecular mechanisms behind the therapeutic response 
mediated by these nanoparticles and their effect on apoptotic pathways. 
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CHAPTER 4: UNDERSTANDING THE CELLULAR RESPONSE OF 
COMBINATORIAL CHEMOTHERAPY AND HYPERTHERMIA IN FREE DRUG 
FORM AND NANOPARTICLE FORM 
 
The purpose of specific aim #2 was to understand the cellular response of combined 
chemo-hyperthermia when administered in free drug form and in the form of 
nanoparticles. In order to understand the cellular effects of different modes of 
hyperthermia when applied in combination with the chemotherapy drug doxorubicin 
(DOX), we used two different hyperthermia types to emulate those administered in 
clinical scenarios:  laser-based rapid rate hyperthermia (which mimics localized 
hyperthermia) and incubator hyperthermia (which mimics whole-body hyperthermia). 
We performed studies to estimate the expression of heat shock protein 70 (HSP70) and 
caspase-3. These are two major proteins that play an important role in apoptosis and 
would help us understand treatment efficacy. 
4.1. Background: 
Hyperthermia involves the application of heat as a cancer therapeutic modality. The idea 
of utilizing heat to kill cancer cells is not novel, however, a practical implementation of 
this approach has been hampered by the lack of technologies that can deliver effective 
and homogeneous heat to deep tumors, as well as a lack of non-invasive technologies to 
monitor temperatures obtained in vivo. Recent developments involving nanotechnology, 
computer modeling, and non-invasive thermometry have once more stimulated an 
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interest in hyperthermia-based cancer therapy. The temperatures commonly used for 
hyperthermia therapy in clinical scenarios are 41-43 °C, because this range of 
temperatures can selectively kill tumor cells without affecting normal cells in vivo 
(Cavaliere 1967). This thermal toxicity is selective towards tumors due to the inherent 
properties of tumor tissue, such as low pH and hypoxia, in comparison to normal tissues 
(Overgaard 1977). The artificially-created temperature rise at the tumor site can elicit 
cytotoxicity by creating irreversible biological damage, or can be used synergistically 
along with other modalities such as radiotherapy and/ or chemotherapy (Kampinga 
2006).  
 
Hyperthermia has been reported to eliminate radiation-resistant tumor cells, thus serving 
as a potential radiosensitizer (Horsman 2007). It also has the ability to kill cells under 
conditions of hypoxia and low pH, which in turn are reasons for developing resistance to 
radiation and chemotherapy (Kampinga 2001).  Hyperthermic temperatures of 43 °C 
have been shown to have more than an additive or synergistic cytotoxic effect when 
employed with several anticancer drugs. One mechanism by which hyperthermia helps 
to enhance drug uptake is through an increase in blood flow and vascular permeability at 
tumor sites (Jain 2005). Hyperthermia has been shown to enhance toxicity when 
administered concurrently with drugs due to an increased intracellular uptake of drugs, 
and increased rate of reactions with cellular targets (e.g. increased DNA damage), as 
well as MDR reversion (Averill and Su 1999; Issels 2008).  
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Hyperthermia is administered clinically through conducting heat sources, or non-
ionizing radiation such as electromagnetic fields in an invasive or non-invasive manner. 
Different techniques for clinical hyperthermia include whole body hyperthermia, 
perfusion hyperthermia of organs, limbs or body cavities, and localized hyperthermia 
(by means of external or internal energy sources), as seen in Figure 2.1 (van der Zee 
2008). Whole body hyperthermia is widely used to treat metastatic cancer by heating the 
patient to a temperature of 43 °C. This form of mild hyperthermia is often used in 
combination with cytotoxic drugs. However, a major limitation of this mode of heat 
administration is its inability to heat deep tumors (Bull 1984).  Perfusion hyperthermia 
is used to regionally heat limbs, organs (liver, pelvis, stomach), or body cavities using 
heated fluids. Perfusion hyperthermia is performed by removing blood, heating it and 
circulating it back (Petrovich 1989). Localized hyperthermia involves elevating the 
temperatures of either superficial or deep tumors without affecting the surrounding 
normal tissues by employing external heating modalities. Non-invasive techniques such 
as high-frequency (e.g. electromagnetic or ultrasound) waves can be employed to heat a 
target region (Marmor 1979 ; Mendecki 1980). This technique is more appropriate to 
treat solid tumors (Storm 1979), and has shown great promise when used with 
chemotherapy for the treatment of prostate carcinoma (Tilly 2005) and bladder cancer 
(Rampersaud 2010).  
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Figure11: Methods for clinical application of hyperthermia (van der Zee 2008)  
 
We have investigated two different thermo-chemotherapy modalities employing DOX as 
a common chemotherapeutic agent, combined with either (1) rapid rate indocyanine 
green (ICG)-mediated laser photo-chemotherapy or (2) incubator-based slow rate 
heating. The ICG-laser-based hyperthermia approach emulates localized hyperthermia, 
whereas incubator-based hyperthermia emulates a whole-body hyperthermia method. 
Our results showed that rapid-rate hyperthermia triggered by exposure of ICG to NIR 
laser (808 nm) showed a synergistic effect with DOX when used in combination with 
this chemotherapeutic drug, whereas slow-rate incubator hyperthermia showed a sub-
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additive effect with DOX (Tang 2009). ICG is a tricarbocyanine dye with near-infrared 
absorption properties (peak absorption around 800 nm), and its ability to generate heat 
upon exposure to NIR illumination was initially investigated several years ago (Chen 
1995). Because body tissues are transparent to the near-infrared portion of the 
electromagnetic spectrum, deeper tissue penetration occurs in this region of the 
spectrum(Anderson and Parrish 1981). This allows for ICG to be used as an in vivo NIR-
based imaging agent for blood volume determination, cardiac output measurement, liver 
function measurements, and visualization of retinal and choroidal vasculature (Benya 
1989). A single treatment with ICG and laser alone was not found to be effective in 
treating tumors, highlighting the need to combine this approach with other treatment 
modalities such as chemotherapy.  
 
When excited by near-infrared (NIR) laser, 5µM ICG is capable of raising cell 
temperature to 43 °C from 37 °C after 3-minute exposure. Incubator induced 
hyperthermia can also increase in vitro temperature to 43 °C, but requiring a longer time 
to reach the temperature. The prolonged duration and slow rate induction of heat can 
induce thermotolerance and reduce the effect of treatment.   
 
Thermotolerance is conferred due to induction of proteins such as heat shock protein 70 
(HSP70) within a time frame of several hours. HSP70 is a class of chaperone protein 
whose role is to help repair misfolded proteins. Therefore, the presence of denatured 
and/or misfolded proteins inside cells provides an input signal for generation of heat 
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shock proteins (Li 1995). The synergy between chemotherapy (DOX) and hyperthermia 
can be decreased if heating is done prior to chemotherapy, because heat exposure prior 
to chemotherapy treatment causes the induction of HSP70 which confers resistance to 
subsequent therapy (Hahn 1976; Herman 1982). A potential approach could be to 
deliver hyperthermia and chemotherapy simultaneously, which is made possible by 
using multifunctional nanoparticles Moreover, drug release from the nanoparticles can 
be controlled to maximize cytotoxic effects. There are a few smart nanoparticle designs 
which employ thermoresponsive polymers to deliver the chemotherapeutic drug upon 
heat exposure, leading to 100% drug release  (Ponce 2006; Yarmolenko 2010).  In terms 
of optimal timing of hyperthermia and other therapies, Overgaard et al. showed that 
application of hyperthermia at 42-43 °C three to four hours after radiation was optimal 
for radiosensitization of cells (Overgaard 1982). Radiosensitization and 
chemosensitization to DNA-intercalating agents such as DOX both result in cytotoxic 
effects by preventing DNA damage repair mechanisms (Kampinga 2001; Blasiak, 
Widera et al. 2003). Therefore, the optimal timing between chemotherapy and 
hyperthermia can be expected to be similar to the timing between radiotherapy and 
hyperthermia. It has also been shown that the rate of heating is a critical factor in 
determining the synergistic effect of hyperthermia and chemotherapy (Herman 1982; 
Tang 2013).  
 
The purpose of this dissertation was to investigate protein expression kinetics in 
response to rapid or slow-rate heating, and provide a rationale for hyperthermia 
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delivered through intracellularly-localized excitable molecules. The proteins under 
investigation were HSP70, to study thermotolerance profiles in cells; and caspase-3 (an 
end-effector apoptotic protein), to understand cellular response to different heating rates 
used with chemotherapy and delivered to cells in free or nanoparticulate form. Some 
previous studies by our laboratory group were focused on the cellular effects of rapid-
rate and slow-rate heating after 24 h exposure, but not on protein expression profile 
during heat exposure (Tang 2009; Tang 2013; Lei 2014). Understanding the kinetics of 
protein expression, on the other hand, would be more useful in understanding cellular 
responses, and would provide a rational approach to choosing appropriate targets and 
planning combinational treatment with other modalities such as radiation or hormonal 
therapy. Previous work in our laboratory has studied HSP70 -induction after rapid-rate 
hyperthermia and slow–rate hyperthermia. However, this work involved the study of 
HSP and caspase-3 expression upon exposure to a single modality (hyperthermia or 
chemotherapy), rather than combinatorial therapy. Additionally, Tang’s work only 
looked at protein expression 24h after exposure. A deeper understanding of protein 
expression kinetics requires investigating earlier time points in order to obtain time-
based expression profiles of HSP70 and caspase-3. In this dissertation, it is hypothesized 
that rapid-rate hyperthermia would induce a faster induction of HSP70 in comparison to 
slow-rate hyperthermia, due to faster denaturation of cellular proteins. However, once 
cell damage becomes too large for the cells to overcome, there would be a down-
regulation of thermotolerance proteins (HSP70 in our case), and this would pave the way 
for cells to undergo apoptosis or necrosis based on the degree and mode of cellular 
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damage. Hence, our study further enhances understanding the cellular events taking 
place upon combinatorial treatment via rapid-rate or slow-rate hyperthermia-
chemotherapy. 
 
4.2. Materials and Methods: 
4.2.1. Drugs and chemicals 
 
Poly (DL-lactide-co-glycolide) (PLGA, L:G 50:50; MW: 40– 75 kDa; glass transition 
temperature (Tg): 45–50 0C), dimethylsulfoxide (DMSO > 99.9% reagent grade), and 
polyvinyl alcohol (PVA, 87–89% hydrolyzed; 13–23 KDa) were purchased from 
Sigma–Aldrich (St. Louis, MO, USA). Dichloromethane (DCM) was purchased from 
Burdick & Jackson (Muskegon, MI, USA). Free-drug formulations were prepared by 
making DOX and ICG solutions as follows: Doxorubicin hydrochloride or DOX 
(Sigma-Aldrich, Saint Louis, MI) solution was prepared by dissolving 10mg DOX 
powder in 1mL of DMSO (Sigma-Aldrich). The desired concentration of DOX was 
obtained by further diluting the stock solution using Dulbecco’s phosphate buffered 
saline (DPBS). ICG (Acros Organic) was stable in solution only up to 8h. Therefore, it 
was desirable to prepare fresh batches before every experiment. Briefly, stock ICG 
solution was prepared by dissolving 1mg ICG in 1mL DI water, and further dilutions 
were obtained using DPBS (Tang 2013). PLGA nanoparticles simultaneously entrapping 
ICG and DOX (designated as IDNP) were prepared using an oil-in-water emulsion 
solvent evaporation technique. The IDNPs were conjugated with anti-HER-2 by means 
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of carbodiimide chemistry and the resulting formulation was denoted as AIDNP 
(Srinivasan 2014). Nanoparticle preparation and characterization have been described in 
great detail in Chapter 1. 
4.2.2. Cell culture: 
Human uterine sarcoma MES-SA cells, and their drug resistant counterpart (P–gP over-
expressing derivative) MES-SA/Dx5 (Dx5) cells, human ovarian carcinoma SKOV-3 
cancer cells, McCoy’s 5A medium, and fetal bovine serum were purchased from 
American Type Culture Collection (Manassas, VA). All three cell lines were cultured 
with McCoy’s 5A media (ATCC) supplemented with 10% fetal bovine serum (ATCC) 
and 1% penicillin-streptomycin (GIBCO, Carlsbad, CA) and maintained in a Heracell 
(Thermo Scientific, Waltham, MA) cell culture incubator containing 5% carbon dioxide 
at 37 °C. Cells were harvested using 0.25% trypsin-EDTA (GIBCO) and sub-cultivated 
at a 1:10 ratio upon confluence. 
4.2.3. Incubator hyperthermia (HT) delivery system and temperature increase profile:  
Previously reported work by Tang et al served as the basis for this experiment (Tang 
2009; Tang 2013). A Hera incubator (Thermo Scientific, Waltham, MA) was used as a 
heat energy source to mimic whole body hyperthermia as mentioned in the introduction 
section. The temperature of the incubator was set to 43 °C. 96-well plates were 
incubated at 37 °C in a separate incubator and later transferred to the 43 °C incubator. A 
temperature calibration study was done to determine the temperature profile of the 
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plates. The temperature calibration was also done for samples containing nanoparticles 
to account for the effect of the nanoparticle solution on the temperature profile. 
 
4.2.4. Laser- HT delivery system and temperature increase profile:  
 
For rapid-rate hyperthermia delivery, ICG was taken up by cells and activated by NIR 
laser. A laser heating system was designed for this purpose. The system is comprised of 
a laser module RLDH808-1200-5, Roithner Lasertechnik, Austria), a laser holder, a 
heated stage insert (WPI Heated Stage Insert, World Precision Instruments Inc, 
Sarasota) and a mobile stage with an extension arm. The whole laser system was 
encased within a box for operator safety and minimization of air currents effect. The 
heating stage insert was placed in a mobile stage below the laser and powered by an 
external source. The plate was used to maintain a temperature of 37 °C. The NIR laser 
source emits light at 808 nm with an output power of 1.2 W. The spot size was 15 mm2 
and the energy density was calculated to be 1440 J/cm2. The small spot size ensured that 
laser power would deliver only to a single well at a time. The laser beam was focused 
onto the designated ICG-containing wells by moving the stage with the help of the 
extension arm outside the box. This extended arm can be used to focus the NIR laser 
beam onto each well one at a time. The experimental setup does not use any optical 
filters or optical lenses to focus the square beam (see Figure 2.2). The temperature 
profile of ICG, IDNP and AIDNP (at a final concentration of 6.5 µM ICG) was 
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measured. Exposures longer than 3 minutes resulted in photobleaching of ICG, and a 
subsequent reduction in heat production.  
 
 
(a)                                                                         (b)  
Figure 12. NIR- Laser system (a) and incubator system (b) used for hyperthermia delivery  (Tang 2009). 
 
4.2.5. Thermal dose calculation 
 
The isoeffective dose was used to compare two hyperthermia treatments of different 
temperature-time modes producing a similar cytotoxic effect. Our previous reports 
suggested that 43 °C incubator hyperthermia showed similar cytotoxicity to 3-minute 
laser-ICG hyperthermia (Tang 2009). The relationship between temperature and time 
can be described using the isoeffective dose equation  
 
                      									ݐଵ = ݐଶ ∗ ܴ భ்ି మ்                                                                                                       
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where t1 and t2 are the durations of treatment at temperatures T1 and T2 respectively. The 
value R is a constant that was calculated by the method described by Sapareto et al., 
(1984). The value of R is assumed to be 0.5 for a temperature of 43 °C. With a slight 
modification of the equation, the cumulative equivalent minutes at 43 °C (CEM43) can 
be measured. The temperature T1 is adjusted to 43 °C, and T2 is varied to obtain an 
integral equation where the upper limit of t is the endpoint time of the experiment (3 
minutes for laser hyperthermia, or 60 minutes for incubator hyperthermia). 
                                                                                      ܥܧܯସଷ = ׬ ܴସଷି்(௧)݀ݐ௧଴                                                         
4.2.6. Thermotolerance detection 
 
Heat shock protein 70 kDa (HSP70) was used to study the expression of induction of 
thermotolerance upon exposure to ICG and DOX in free form or in nanoparticle form 
(IDNP, AIDNP; (corresponding to final ICG and DOX concentrations of 6.5 µM and 10 
µM respectively in the cell culture media). ELISA was used to measure HSP70 
induction after post-treatment times of 4, 6, 8, 12, 16, and 24 h. The protein levels were 
normalized to their respective controls (those which received no treatment) and cell 
growth fractions were used to report cell viability after each treatment. 
 
4.2.7. Mode of cell death 
 
Caspase-3 is an end-effector protein which is responsible for the initiation of 
intracellular events in apoptosis. A caspase-3 activity assay kit (Roche Applied Science, 
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Indianapolis, IN) was used to measure caspase-3 levels after the different combinatorial 
therapies. This is a fluorometric immunosorbent enzyme assay (FIENA) for the 
quantitative determination of caspase-3 activity in 96-well plates pre-coated with anti-
caspase-3 agent. Caspase-3 levels were quantified 4, 6, 8, 12, 16 and 24 h after the 
hyperthermia treatment and normalized to their respective control, which is the caspase-
3 value from cells that did not receive any treatment; and to SRB values to take into 
consideration cell viability upon each of the treatment conditions. 
 
4.3. Results and Discussion: 
 
Hyperthermia is gaining popularity in its application as an adjuvant therapy 
administered with chemotherapy, and has shown a synergistic effect along with some 
cancer drugs (Kampinga 2006; Ko 2006). Its efficacy when used alone or in 
combinatorial therapy depends on temperature achieved, duration of treatment, and rate 
of heating (Sapareto 1984; Tang 2009). 
 
The thermal dose in the form of CEM43 °C (or CEM43, the cumulative equivalent 
minutes at 43 °C) was calculated using method by Sapareto et al. (Sapareto 1984). The 
calculations were performed for both rapid-rate ICG laser hyperthermia and incubator 
hyperthermia in the presence of nanoparticles (IDNP and AIDNP). Laser-ICG 
hyperthermia at 3 min exposure produced a much lower thermal dose compared to the 
43 °C incubator hyperthermia treatment, when delivered through nanoparticles. These 
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results are consistent with our previous report on similar experiments done with free-
form ICG or nanoparticle-form IR820 (Tang 2009; Lei 2014). IR820 is an ICG 
derivative with a chloro-substituted cyclohexene group). ICG and IR820 are both near-
infrared dyes which can generate hyperthermia. At 5µM concentration and exposure to 
3min laser (λ= 808 nm; energy 1440 J/cm2), these dyes produce a temperature increase 
within the desired range required to kill cancer cells, i.e., 41-45 °C (Tang 2009; 
Fernandez-Fernandez 2012; Tang 2013; Lei 2014; Srinivasan 2014). A CEM43-based 
thermal dose model is used to express the thermal load onto the living cells or tissues by 
inducing the given thermal stress in specific time duration. For example, the CEM43 for 
skin tissues corresponds to 16 min, which produces similar cell growth as 64 min at 42 
°C, or 1 min at 47 °C (Murbach 2013).  The higher CEM43 and slower rate of heat 
generation observed in the temperature-time profile of incubator hyperthermia, in 
comparison to laser-ICG hyperthermia, suggests that thermotolerance may be induced 
during incubator hyperthermia.  Figure 13 shows that the temperature profile during free 
ICG-laser hyperthermia reaches a higher peak temperature than when using 
nanoparticles (i.e., IDNP and AIDNP). This could be due to the fact that the nanoparticle 
shell prevented the diffusion of heat from the nanoparticle core to the surrounding 
media. The overall thermal dose required is dependent on the area under the curve of the 
temperature-time profile, and the heating time using the laser (808 nm; 6.7 W/cm2 
fluence rate) is dependent on providing an isoeffective dose in comparison to that 
provided in incubator hyperthermia. There is a temperature reduction seen at the 180 sec 
time point, which could be caused by possible degradation of ICG due to heat or laser.  
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The laser irradiation duration of 3 min was chosen because it helped potentiate 
maximum combinatorial therapy in all the three cell lines MES-SA, MES-SA/Dx5 and 
SKOV3 cell lines (Tang 2010) 
 
 
Figure 13: Temperature profile during hyperthermia treatment. (a) Temperature generation as a function 
of ICG in free form and nanoparticles form each at a concentration of 6.5 µM (n = 3). Data are presented 
as mean ± SD; (b) temperature elevation profile during 43°C incubator hyperthermia (done in presence of 
ICG and ICG-loaded nanoparticles to know their effect (n= 1). 
 
Exposure of cells to thermal stress causes either cell killing or induction of 
thermotolerance, depending on the thermal dose provided. The direct effect of heat 
which leads to either cell killing or thermotolerance involves protein denaturation. 
Thermodynamic arguments (Johnson 1974) and the requirement of high activation 
energy (Westra 1971) suggest a correlation between protein denaturation and cell 
killing. Similar correlations also exist between protein denaturation and heat-shock 
protein induction, which is widely involved in cellular thermotolerance. This theory has 
been proved by the fact that injection of denatured proteins and immediate induction of 
proteolytic signals has served as a trigger for induction of heat shock protein expression. 
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Thus, there seems to exist a common pathway connecting cell killing, thermotolerance, 
and heat shock protein induction, all of which are a consequence of cellular protein 
denaturation (Hahn 1990).  Cellular proteins retain their flexibility and plasticity at the 
optimal temperature T required for their proper functioning. Exposure to heat (at 
temperatures above this optimal temperature T) makes proteins thermolabile and 
susceptible to causing stress in their host cells.  Spectroscopic and differential scanning 
calorimetric studies have suggested that protein denaturation is the cause of thermal 
damage to cell membranes and organelles (Lepock 1983; Lepock, Cheng et al. 1987; 
Lepock 1989). Therefore, there exists a level of protein denaturation which either causes 
hyperthermic cell killing or heat shock protein-based thermotolerance (Lepock, Frey et 
al. 1993). The level of thermal damage decides the level of protein denaturation, which 
in turn decides its fate as (1) being processed by molecular chaperones through HSP 
induction or (2) when the repair is irreversible, damaged proteins are degraded by means 
of the ubiquitin–proteasome pathway which plays a critical role in apoptosis (Murata 
2003). This phenomenon is also important in the case of combined thermo-
chemotherapy. A description of the two pathways is provided in the following 
paragraphs. 
 
Thermo-chemosensitization of cells in combined therapy can either cause enhanced or 
reduced effects due to induced thermotolerance. Thermotolerance, also known as 
thermal preconditioning, is an effect by which cells can tolerate sub-lethal heat stress 
after they have been previously exposed to heat. Thermotolerance is often achieved 
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when cells are exposed to mild heat treatment that involves reversible damage to labile 
proteins, as well as  acceleration of cellular metabolic process by expression of anti-
apoptotic proteins such as heat shock proteins (Kregel 2002.).  Heat treatment of cells 
causes proteins to unfold from their native state, preventing them from performing their 
functions inside the cell. The presence of these malfolded proteins inside cells causes the 
induction of molecular chaperones, which help refold these proteins into their native 
folded state (Frydman 2001). Heat shock proteins belong to this class of molecular 
chaperones that help with proper folding of newly synthesized proteins and/or refolding 
misfolded proteins (Baler 1992; Lepock 2005.).  However, heat shock protein induction 
is dependent on several factors including temperature, duration of exposure, and cell 
type. Protein denaturation is the rate-limiting step of heat shock protein generation. Most 
mammalian cells respond to a temperature increase of 5-6 °C if their ambient growth 
temperature condition is at 37 °C (Morimoto 1996.). The signaling of heat shock protein 
is driven by heat shock transcription factors (HSF), as shown in Figure 2.3. HSFs are 
stress-induced and do not contribute to the constitutive levels of HSP (Huang 2001). In 
the absence of stressful conditions, HSPs are in their inactive form where HSPs are 
bound to HSFs.  When cells undergo stress, HSFs are dissociated from HSPs and 
translocate to the nucleus. Inside the nucleus, HSFs bind to the promoter region of the 
HSP operon known as the heat shock element (HSE) which transcribes and 
overexpresses HSPs (Kiang 1998; Huang 2001; Trinklein 2004). The proteins that are 
irreversibly damaged during thermal stress undergo degradation via the ubiquitin-
proteosome complex in the lysosome (Bond 1988).  However, when the  level of thermal 
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damage is much higher than the activation energy for cell killing, the damaged or 
denatured proteins accumulate and lead to cell killing (Lepock 2003).  
 
Figure 14: Schematic of Hsp70 response pathway in cells (Morimoto 1996). 
 
Our protein expression data after combinatorial therapy suggests that there is a transient 
and rapid overexpression of HSP70 (peaking at 6h) in rapid-rate laser hyperthermia-
chemotherapy, in contrast to a slower rate of induction of HSP70 expression (peaking at 
8h) in slow-rate incubator hyperthermia-chemotherapy. The transient overexpression of 
HSP70 suggests the presence of denatured proteins upon heat stress. These results are 
consistent with Beckam and coworkers (Beckham 2004). Differences between the two 
modes of combinatorial therapy are to be expected, because the rapid-rate heating 
induced by laser therapy is likely to induce faster cellular protein denaturation in 
comparison to slow-rate incubator hyperthermia, and protein denaturation is the rate-
limiting step for HSP generation. Chen and coworkers also suggested a similar effect in 
gold nanorod-mediated photothermal therapy. Laser photothermal therapy causes heat 
generation in cells at a rapid rate, resulting in sudden local heating and thermal 
explosions which induce rapid protein denaturation and damage in cellular structures. 
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This damage can compromise cell membrane integrity and hence increase drug 
permeability in combinational therapy (Chen 2010). Beckam and coworkers also 
showed that HSP70 expression upon laser irradiation and incubator hyperthermia 
conditions peak around 4-8 h post-treatment, and then decrease after 12 h incubation. 
This delayed response could be because there needs to be sufficient time for the HSP70 
gene promoter to receive the signal to activate transcription from HSF1 to the required 
mRNA, and for further production of the functional protein to occur, as suggested in the 
schematic of HSP70 response in Figure 3. The earliest time of HSP70 response has been 
reported as 2-3 hours post heat stress. The up-regulation of mRNA levels itself takes 
about 90 minutes (Amici 1992).  Yang and coworkers observed transient expression of 
HSP70 upon exposure of MCF-7 breast cancer cells to Apt-Au-GO nanocomposites at 
1.74 µg/mL concentration using a NIR laser (λ= 808 nm, 5 min exposure time) for 
photothermal therapy. They reported that there was a transient expression of HSP70 at 3 
h, followed by a down-regulation of these proteins at 12 and 24 h. They explained their 
results by suggesting that cells undergo two stages upon heat exposure: a compensatory 
stage, as the cell tries to overcome the presence of damaged proteins by overexpressing 
HSP70; and a decompensatory stage, where induced HSP70 is unable to repair heat-
damaged proteins due to irreversible damage. In this decompensatory stage, HSP70 
induction is down-regulated and the cell is allowed to switch to cell death mechanisms 
through apoptosis or necrosis (Yang 2015).  
Appropriate heat deposition in cancer cells through the careful choice of laser 
parameters can help in increasing the efficacy of the heat treatment when used alone or 
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in combined therapy. The goal is to achieve significant temperature elevation, decreased 
cell viability, and down-regulation of HSP expression, leading to a successful cancer 
treatment alternative as suggested by Fisher and coworkers (Fisher 2010). They 
employed MWCNTs for photothermal cancer therapy and reported that lower heat 
duration (1.5 W/cm2, 1.5 min) upregulated HSP and increased cell viability, whereas 
higher irradiation duration (1.5 W/cm2, 5 min) downregulated HSP and lowered cell 
viability. Successful thermal therapies hence lead to downregulation of HSP70 and 
induce biological effects such as cell membrane blebbing and necrosis (Diederich 2005). 
When HSP70 is downregulated, the Bax protein is translocated from the cytosol into 
mitochondria, resulting in the formation of pores to release cytochrome c and apoptosis-
inducing factor (AIF). The released AIF translocates to the nucleus to induce cell death 
(Jürgensmeier 1998). This suggests that HSP70 is a potential anti-apoptotic protein 
(Rérole 2011). Transient exposure to mild elevated temperatures is tolerable, since cells 
can rapidly turn on their repair mechanisms. However, above a given time and 
temperature threshold, the cell will succumb to death. Therefore, cellular fate ultimately 
depends on the relative strength of cell death and cell survival signals. 
When looking at the HSP70 generation profile in different cell lines for a given mode of 
hyperthermia, we see that different cell lines show similar profiles, as long as the 
hyperthermia mode is the same. That is, when looking at rapid-rate hyperthermia-
chemotherapy combination therapy, the HSP70 generation profile is similar in cell lines 
MES-SA, MES-SA/Dx5 and SKOV3. When looking at the HSP70 generation profile of 
slow-rate hyperthermia-chemotherapy, cell lines also showed similar profiles when 
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compared to one another. These results indicate that the thermosensitivity of cells with 
different drug sensitivity or resistance is the same. Similar results have been reported by 
Asaumi and coworkers, who found similar thermosensitivity in drug-sensitive and multi-
drug resistant Ehrlich ascites tumor cells (Asaumi 1996). Wrzal and coworkers also 
showed that drug-sensitive and multi-drug resistant Chinese Hamster ovarian cells 
exhibited similar thermosensitivity (Wrzal 2008). In our work, incubator-hyperthermia-
chemotherapy exhibited a time-dependent increase in caspase-3 expression in all three 
cells lines under study, MES-SA, MES-SA/Dx5 and SKOV3, with significant 
expression starting from 12 h. Laser-hyperthermia-chemotherapy exhibited the same 
levels of caspase-3 expression at all post-irradiation times and in all three cell lines.  
These results can be explained on the basis of previous reports by Tang and coworkers 
in our laboratory, who showed that incubator-hyperthermia-chemotherapy showed a 
sub-additive effect of therapies and induced apoptosis in cells, and laser-hyperthermia-
chemotherapy exhibited a synergistic effect of therapies and induced necrosis (Tang 
2013).  These results are consistent with literature stating that caspase-3 proteins are the 
end effectors of apoptosis which trigger a further cascade of apoptosis- executors for 
DNA fragmentation and chromatin condensation (Cohen 1997). However, they are 
completely downregulated in the necrosis processes (Denecker 2001 ). 
Our results show that peak HSP70 expression was comparable after exposure to AIDNP, 
IDNP and ICG- DOX based laser therapy or incubator therapy in MES-SA cells. The 
same can be said for peak caspase-3 expression in MES-SA cells, which was 
comparable across treatment groups (See Figure 2.5).  In MES-SA/Dx5 cells, both 
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HSP70 and caspase-3 showed higher generation for AIDNP and IDNP, in contrast with 
free form ICG-DOX based laser therapy and incubator therapy (See Figure 2.6). Finally, 
in SKOV-3 cells, AIDNP treatment caused much higher HSP70 and caspase-3 
generation than IDNP and ICG- DOX based laser therapy and incubator therapy (See 
Figure 2.7). 
 
Figure 15 HSP70 and caspase-3 induction after incubator hyperthermia (a&c) and laser hyperthermia 
treatment (with or without chemotherapy) (b&d) in MES-SA cells (n=3). denotes peak expression of 
protein. * denotes statistical significance between treatment groups (p <0.05). 
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Figure 16. HSP70 and caspase-3 induction after incubator hyperthermia (a&c)(e&f) and laser 
hyperthermia treatment (with or without chemotherapy) (b&d) in MES-SA/Dx5 cells (n=3). denotes 
peak expression of protein . * denotes statistical significance between treatment groups (p <0.05). 
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Figure 17.  HSP70 and caspase-3 induction after incubator hyperthermia (a & c) and laser hyperthermia 
treatment (with or without chemotherapy) (b & d) in SKOV-3 cells (n=3).  denotes peak expression of 
protein. * denotes statistical significance between treatment groups (p <0.05). 
These results can be explained based on an understanding of cell characteristics and their 
drug sensitivity or resistance. MES-SA cells are drug-sensitive uterine cancer cells and 
hence, uptake of ICG and DOX into these cells occurs both in the free form and in 
nanoparticles. Therefore, there is no advantage to a nanoparticle formulation of ICG and 
DOX because the free form can already be delivered to these cells. MES-SA/Dx5 is a 
drug-resistant variant of MES-SA cells that overexpresses a multidrug-resistance pump, 
P-glycoprotein. The incorporation of ICG and DOX into nanoparticles in the form of 
IDNP and AIDNP is able to have a competitive advantage over the agents in free form, 
because nanoparticles bypass the multidrug-resistant protein overexpressed in these cells 
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so that entrapped agents can be delivered more efficiently into the cell. SKOV3 is a 
drug-resistant ovarian cancer cell line with a p53 gene deletion. These cells overexpress 
HER-2 receptors. AIDNP are nanoparticles containing ICG and DOX, and which have 
been surface-conjugated with an antibody to HER-2 receptors. Hence, SKOV3 exhibit a 
higher uptake of ICG and DOX in the form of AIDNP than IDNP or free form (ICG and 
DOX) (Tang 2010; Srinivasan 2014). The uptake of the hyperthermia agent (ICG) 
shows differential intracellular availability when delivered through different 
nanoparticle forms (AIDNP and IDNP) or as free drug in cells with different drug 
sensitivity or resistance properties. The delivery of different heat modalities to 
intracellularly-accumulated ICG further causes a differential protein response as 
hyperthermia exerts its toxic effect. For example, AIDNP showed the highest uptake in 
SKOV-3 in comparison to ICG and DOX delivered through other forms (IDNP and ICG 
and DOX). As a result, higher ICG intracellular availability and subsequent heat 
generation causes more extensive protein denaturation and higher HSP expression in 
comparison to the same agents delivered through IDNP or  free form. The uptake of the 
hyperthermia agent (ICG) determined intracellular availability, and the mode of 
hyperthermia (laser or incubator) also affects the extent of intracellular damage and the 
amount and timing of protein expression (HSP70 and capase-3). 
Conclusions: 
Our study demonstrated a transient expression of the anti-apoptotic protein HSP70 in 
rapid-rate ICG-laser-chemotherapy and slow-rate incubator hyperthermia-chemotherapy 
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applied to cancer cells. Previous work done in our laboratory by Tang showed a 
differential HSP response of rapid-rate and slow-rate hyperthermia 24 h post-treatment 
(Tang 2013). The present dissertation focuses on studying the HSP generation profile 
from the above mentioned hyperthermia modes in combination with chemotherapy 
(instead of hyperthermia alone), and also includes earlier time points. A faster HSP70 
response was seen in rapid-rate ICG-laser-chemotherapy in comparison to slow-rate 
incubator hyperthermia-chemotherapy.  HSP is expected to be dependent on the level of 
protein denaturation in cells. Because rapid- rate hyperthermia induces a faster and 
greater percentage of protein denaturation, we can expect to observe faster generation of 
HSP in comparison to slow rate hyperthermia. Cells with different drug sensitivity or 
drug resistance showed similar thermosensitivity. A time-dependent increase of caspase-
3 was observed in slow-rate incubator hyperthermia-chemotherapy indicating apoptotic 
cell death; however, a flat response of caspase-3 was induced in rapid-rate ICG-laser- 
chemotherapy, indicating necrotic cell death in cancer cells. AIDNP, IDNP (ICG and 
DOX entrapped into nanoparticles) and free ICG and DOX showed different HSP70 and 
caspase-3 responses in cancer cells with different drug sensitivity or resistance. The 
observed pattern of HSP70 and caspase-3 generation must be taken into account to 
understand the efficacy of the combinatorial hyperthermia-chemotherapy treatment 
rendered through two different hyperthermia methods, and it can assist planning when 
used in combination with other treatment modalities such as radiation therapy. 
Understanding the timing of expression of anti-apoptotic and apoptotic proteins can help 
in making decisions of when to add other treatment modalities to the combinatorial 
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therapy. For example, additional radiation or hormonal therapy can be provided 12 h 
after combinatorial hyperthermia-chemotherapy treatment, because both rapid-rate-
hyperthermia-chemotherapy and slow-rate-hyperthermia-chemotherapy result in down-
regulation of HSP post-treatment. As a result, cells can be more sensitive to other 
treatment modalities.  
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CHAPTER 5: MULTIFUNCTIONAL SILVER NANOPARTICLES FOR TARGETED 
CANCER THERAPY AND UNDERSTANDING THEIR MECHANISM OF ACTION 
Our work described in the previous chapters has shown that polymeric nanoparticles 
loaded with chemotherapy and hyperthermia agents, and decorated with receptor-
specific targeting moieties, can be used to produce enhanced toxicity in cancer cells 
compared to treatment approaches using a single modality or a non-targeted nanoagent. 
Furthermore, the application of hyperthermia via an intracellular agent results in 
enhanced response to the treatment compared to environmental hyperthermia such as 
that produced by an incubator, which mimics whole body hyperthermia. Localized 
hyperthermia, when used in combination with chemotherapy, shows faster HSP70 
response in comparison to similar treatment using incubator hyperthermia and 
chemotherapy. The mode of cell death is also different: combined chemo-laser 
phototherapy causes necrotic cell death, in contrast to apoptotic cell death which is 
observed in combinatorial chemo-incubator hyperthermia. 
These observations support the use of targeted multifunctional agents in the treatment of 
cancer using combined chemotherapy and hyperthermia. However, there are some 
concerns with the use of polymeric nanoparticles as therapeutic carriers. Some of their 
disadvantages include toxicity of preparation solvents, acidity of degradation 
byproducts, and drug release profiles which are typically biphasic and may be difficult 
to control (Fernandez-Fernandez 2011).  
An additional concern regarding dual agent multifunctional nanoparticles is brought by 
the shortcomings of both doxorubicin and indocyanine green. Nanoparticle 
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encapsulation of DOX decreases its off-target toxicity and helps circumvent the 
development of resistance, but there are still problems in achieving a predictable release 
profile from a polymeric nanoparticle in terms of timing, as well as in reaching desired 
concentrations in tumor tissue. One of the major constraints in terms of the effects of 
different timing of combined chemotherapy and hyperthermia is the possible induction 
of thermotolerance. Thermotolerance can be induced if the hyperthermia agent is 
released first and exposed to the laser to generate heat, inducing overexpression of heat 
shock protein that can confer cell resistance to subsequent chemotherapeutic treatment. 
This has the potential to decrease the efficacy of the treatment combination. Therefore, 
we ideally want to avoid premature release of the hyperthermia agent. Thus, a drug 
delivery system with simultaneous incorporation of hyperthermia agent ICG and 
chemotherapy agent DOX would be required to have slower release of ICG compared to 
the release rate of DOX in order to avoid induced tolerance effects.  
In practical terms, this means that design optimization is much more challenging as one 
must simultaneously optimize the release rate of two agents. Selecting and designing a 
polymeric vehicle that can carry two agents with completely different physicochemical 
properties, while also providing differential customized timing for their release, becomes 
quite complicated. For instance, ICG is amphiphilic, whereas DOX is hydrophobic.  A 
hydrophobic polymer will interact more with DOX, thereby entrapping more DOX 
compared to ICG. Reduced ICG entrapment will result smaller overall amounts of ICG 
released at the target site. A hydrophilic polymer, on the other hand, will interact more 
with the amphiphilic agent ICG, thereby entrapping more ICG and less DOX and hence 
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release smaller amount of DOX at the target site. Neither of the two options will be 
optimal for combinatorial treatment purposes.  Therefore, simultaneous entrapment of 
therapeutic agents into a polymeric system (with appropriate hydrophobicity to 
hydrophilicity ratio) with the optimal dose of both agents and with optimal release for 
effective treatment can be difficult to achieve in practice. In the case of indocyanine 
green, an additional concern is its poor stability in aqueous solution, which can limit its 
therapeutic window once it is released from the nanoparticle. This could be 
circumvented by selecting a more stable dye, although the question of dual entrapment 
optimization would still remain. Finally, burst release of agents on the surface of 
polymeric nanoparticles can further alter dosage and timing of agent delivery at the 
target site.  
Another consideration that limits the application of a polymeric multifunctional system 
is that most polymeric nanoparticles do not possess inherent imaging capabilities, unlike 
metal nanoparticles, and hence polymeric nanoparticles depend on the imaging 
capabilities of the agents they entrap.  
When considering these disadvantages, it becomes clear that a possible alternative to 
multifunctional polymeric nanoparticles with dual agent entrapment is the use of metal 
nanoparticles with inherent multifunctional capabilities for imaging and phototherapy. If 
we use these nanoparticles to deliver a chemotherapeutic drug, we obtain a 
multifunctional system capable of image-guided therapy with combinational 
chemotherapy and phototherapy. In this case, optimizing the release kinetics of the 
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chemotherapy agent is much easier than if we had to deal with multiple agents. This 
helps in achieving higher control over the system, and makes it easier to attain clinically 
relevant dosing and timing for combined therapy at the target site.  
Metallic nanoparticles have unique optical properties related to surface plasmon 
resonance (Levi-Polyachenko 2011). Also, the size and shape of metallic nanoparticles 
can be more easily controlled compared to polymeric nanoparticles, and this creates the 
option of tailoring particle size to the specific application as well as for their appropriate 
phototherapeutic application. Although AgNPs are slightly less chemically stable than 
gold nanoparticles, they have potential advantages in other applications such as SERS 
sensing, based on their higher extinction coefficient and large effective scattering cross-
section(Caro 2010). Boca et al reported the successful use of chitosan-coated silver 
nanotriangles (Chit-AgNTs) with resonances in the near-infrared (NIR) as localized 
hyperthermia agents against a line of human non-small lung cancer cells (NCI-H460) 
(Boca 2011). Silver nanoparticle formulations have been shown to have cytotoxic effects 
in several cancer cell lines, including MCF-7 breast cancer cells (Franco-Molina 2010), 
human epidermoid larynx carcinoma (Satyavani 2012 ), acute myeloid leukemia (Guo 
2014 ), human epithelial carcinoma cell line HeLa (Sukirtha 2011), Dalton’s lymphoma 
(Sriram 2010). Sriram’s group was able to show that mice treated with Ag NPs had 
survival times increased by 50% with respect to controls, as well as decreased volume of 
ascites and decreased cancer cell count and white blood cell count within ascitic fluid 
(Sriram 2010). Sukirtha et al also demonstrated increased lifespan in a lymphoma mouse 
model after treatment with AgNPs (Sukirtha 2011). Gurunathan's group has reported that 
141 
 
AgNPs can act as an antiangiogenic molecule, which could be a very important weapon 
to create an unfavorable environment for tumor tissue (Gurunathan 2009 ). The 
cytotoxic effect of AgNPs seems to be mediated by generation of reactive oxygen 
species as well as release of silver ions which interfere with mitochondrial activity (Guo 
2013). However, silver appears to be not toxic against healthy cells, and Franco-Molina 
reports that mice exposed to 50x the recommended manufacturer’s dose of colloidal 
silver for one year showed no negative effects on fertility and tumor development 
(Franco-Molina 2010).  
Based on these advantages, the next step in our project was to develop a modified 
approach using targeted AgNPs that could be utilized in combinational chemotherapy 
and hyperthermia treatments while reducing some of the concerns created by the dual 
agent - polymeric nanoparticle strategy. In choosing a targeting moiety to use with our 
AgNPs, we took into account the chemical feasibility and practicality of binding the 
moiety to AgNPs, as well as biological considerations such as biocompatibility and 
ability to target cancer tissue. We chose folate because it can be bound to AgNPs via a 
sulfhydryl link, it is a natural targeting moiety that would not cause immune response in 
humans, and it is overexpressed in about 90% of ovarian cancers (Figini 2003). The next 
chapter moves on to describe the development and use of folate-capped AgNPs in 
combinational cancer therapy.  
 The purpose of specific aim# 3 is thus to prepare multifunctional silver nanoparticles 
(AgNPs) for targeted cancer therapy. The AgNPs serve as therapeutic agent as it is seen 
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to mediate toxicity by generation of reactive oxygen species. The chemotherapeutic 
agent DOX is attached to AgNPs through a pH-sensitive linkage to allow for pH-driven 
drug release. The mechanism underlying the action of these nanoparticles is also studied 
in this chapter.  
5.1. Introduction: 
Multifunctional agents have the potential to improve diagnosis and treatment of cancer 
patients by facilitating a holistic approach to patient management. These agents employ 
combined diagnostic and therapeutic modalities, which help in simultaneous localization 
and treatment of tumors (Janib 2010; Xie 2010; Fernandez-Fernandez 2011; Lu 2014). 
The method of combining diagnostic and therapeutic modalities is often referred to as 
“theranostics” (Caro 2010; Özdemir 2012). An important issue in cancer management is 
that diagnostic and therapeutic agents often have different biodistribution and 
selectivity, creating challenges in planning, timing, monitoring, and measuring treatment 
success. Multifunctional agents confer an advantage by allowing the combination of 
diagnostic and therapeutic agents onto a single platform. As a result, site localization can 
be coordinated with therapeutic action so that treatment occurs at the correct location 
and is also timed appropriately. Additionally, the effect of therapy can be monitored in 
real time thanks to the diagnostic capabilities of the multifunctional agent.  
Nanomedicine is a rapidly progressing area in the field of cancer therapy which provides 
an effective platform to combine more than one therapeutic and/or diagnostic modality.  
Nanoscale theranostic systems that have emerged for cancer treatment include organic 
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polymer based and organic-inorganic nanocomposite based systems (Pregibon 2007; 
Kim 2008; Neoh 2011; Srinivasan 2014). These systems have several potential 
advantages over conventional single small molecule-based therapies, some of which 
include high payload capacity, prolonged blood circulation times, reduced toxicity to 
healthy tissues, and improved anti-tumor efficacy (Blanco 2009). 
Inorganic plasmonic nanoparticles such as gold and silver possess several unique optical 
properties, and hence have been used in a wide range of biomedical applications such as 
sensing, imaging and therapy (El-Sayed 2005; Sriram 2010). Metal nanoparticles are 
prepared by reducing a salt solution of the metal. Commonly used reducing agents used 
in the synthesis of silver and gold nanoparticles include borohydride, citrate, ascorbic 
acid, and organometallic compounds such as dimethylformamide and polyols. These 
reducing agents can sometime be interchangeably used as capping agents as well. 
Recent developments in metal nanoparticle synthesis involving different capping agents 
have helped to prevent nanoparticle aggregation as well as to reduce nanoparticle 
toxicity, thereby making nanoparticles more suitable for application as drug delivery 
vehicles (Shon 2004; Huynh 2011).  
Among the plasmonic nanoparticles, AgNPs are gaining considerable attention due to 
their favorable physicochemical attributes such as magnetic and optical polarizability, 
electrical conductivity, catalysis, antimicrobial behavior, and Surface-Enhanced Raman 
scattering properties (El-Sayed 2005). AgNPs also have very diverse biomedical 
applications in wound dressings, contraceptive devices, surgical instruments, and bone 
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prostheses to prevent microbial activity; and have been widely investigated for their 
antimicrobial and antifungal properties (Sharma 2009; Sau 2010). AgNPs have been 
employed less in the development of drug delivery vehicles because they exhibit lower 
chemical stability than gold nanoparticles. However, AgNPs possess some attributes that 
could confer an advantage over gold nanoparticles, such as higher extinction 
coefficients, sharper extinction bands, higher ratio of scattering to extinction, and 
extremely high field enhancement (Carlos Caro 2010). As a result, a lot of interest has 
arisen recently in the application of AgNPs in cancer therapy. These nanoparticles serve 
as promising drug carrier candidates thanks to the ability to control their size, facile 
surface modification, and adequate cell penetration (Sriram 2010; Guo 2013). Careful 
and thoughtful design of nanoparticle systems can tailor drug release by making 
formulations responsive to internal or external triggers such as pH change, intracellular 
glutathione levels, light or temperature changes, etc. (Hong 2006; Aryal 2009; Smeta 
2011; Zhang 2012). AgNPs can also be useful in photodynamic applications, as they 
generate cytotoxic reactive oxygen species when irradiated with suitable light 
wavelengths (Corato 2012). Several researchers have shown synergistic chemo-
photodynamic therapy through combinations of chemotherapeutic and organic dye-
based photosensitizers (Penga 2008; Lu 2014). However, nanoparticle based 
photosensitizers could provide a better alternative to organic dye-based photosensitizers 
because they do not undergo photobleaching. Gold (AuNPs) and silver nanoparticles 
(AgNPs) are both potential photosensitizers having the ability to produce reactive 
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oxygen species upon laser irradiation. The advantages of AgNPs as described above 
make them an ideal drug delivery vehicle for combined chemo-photodynamic therapy. 
Doxorubicin is a chemotherapeutic drug used for the treatment of a wide spectrum of 
tumors. It belongs to the class of anthracycline antibiotics, which exhibit their cytotoxic 
effect by intercalating with nuclear DNA and inhibiting topoisomerase II  (Belloc 1992; 
Gieseler 1994). Some of the limitations of this drug include its non-specific 
cardiotoxicity and the development of drug resistance in cancer cells  (Singal 1998; 
Gottesman 2002). A possible way of enhancing the therapeutic efficacy of DOX is by 
utilizing prodrug designs that increase drug concentration at target sites while reducing 
off-site toxicity. Nanoparticle formulations that allow for triggered release of DOX 
provide a good way to achieve this effect. 
With the goal of creating a multifunctional agent with high selectivity, an additional 
advantage of using nanoparticle formulations is the ability to attach ligands that bind to 
specific target receptors. The folate receptor (FR) is highly overexpressed in several 
human malignant tumors, in comparison to normal tissues (Weitman 1992). Folic acid 
(FA) is a widely-used ligand which possesses high affinity to folate receptors 
overexpressed in cancer cells. Therefore, FA and its conjugates demonstrate 
significantly enhanced delivery to FR-positive tumor cells (Zhang 2004; Hilgenbrink 
2005). Folic acid conjugates are internalized through folate receptors, dissociate in the 
intracellular environment of cancer cells (pH = 5.0 ~ 5.5 of endo-lysosomes) and then 
are released into the cytosol (Antony 1992; Sudimack 2000). 
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The current manuscript describes a multifunctional folate-targeted silver nanoparticle-
based theranostic system that combines the cytotoxic photodynamic properties of 
AgNPs with the chemotherapeutic properties of DOX, which is tethered to the 
nanoparticle through a pH-sensitive linker. Upon cargo release inside the cancer cells, a 
combined chemo-photodynamic effect can be achieved. These multifunctional 
nanoparticles can also be probed intracellularly through Raman and fluorescence 
spectroscopy for diagnostic and treatment monitoring purposes. Thus, in addition to 
active targeting with FA, the selectivity of the nanoparticles is also attributed to 
activation by near-infrared (NIR) laser once the particles have been confirmed to be 
localized at the tumor site. 
5.2. Materials: 
Heterobifunctional polyethylene glycol (PEG), MW 5kDa, was obtained in two forms: 
one with a sulfhydryl group at one end and a carboxyl group at the other end (SH-PEG-
COOH, MW: 5kDa), and another form with a sulfhydryl group at one end and an amine 
group at the other end (SH-PEG-NH2, MW: 5kDa). Both forms were purchased from 
Nanocs, New York, NY. Silver nitrate, hydrazine hydrate, trifluoroacetic acid, N,N'-
Dicyclohexylcarbodiimide (DCC) and N-Hydroxysuccinimide (NHS) were obtained 
from Fluka (Sigma-Aldrich, St. Louis, MO). All chemicals used were analytical grade. 
HCl and HNO3 were purchased from Sigma-Aldrich, St. Louis, MO, and used to prepare 
aqua regia (HCl and HNO3 in 3:1) to wash all glass apparatus used in the preparation of 
the colloidal AgNPs. Deionized water used in the experiments had a resistivity of greater 
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than 18 mega ohm-cm. The cell lines MES-SA (human uterine sarcoma, DOX sensitive 
cell line), MES-SA/Dx5 (DOX resistant counterpart cell line of MES-SA) and SKOV3 
(drug resistant ovarian carcinoma) were obtained from America Type Culture Collection 
(Manassas, VA, USA). 
5.3. Methods: 
5.3.1 Preparation and characterization of silver nanoparticles: 
Citrate-stabilized AgNPs were produced using a previously described method of 
reducing a boiling solution of silver nitrate in the presence of trisodium citrate (Lee 
1982). Briefly, 100 ml of 1 mM AgNO3 aqueous solution was boiled to 100 °C, and then 
7 ml of 1% trisodium citrate solution were added. The mixture was kept at constant 
temperature of 100 °C for about 1 hour and then was allowed to cool down to room 
temperature. The resultant colloidal mixture was of dark grey color.  The AgNPs were 
characterized for their size through UV-visible spectroscopy using a Cary UV 
Spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). Size was confirmed 
by Dynamic Light Scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK), which was used to measure zeta potential. 
5.3.2. Preparation of Folate and DOX conjugates: 
5.3.2.1 Folate-PEG conjugate (hereafter referred to as FP conjugate):  
Folate-PEG was synthesized via amide bond formation. Briefly, folic acid was reacted 
with DCC and NHS in anhydrous DMSO in molar ratio 1:1:1.2; Folic acid/ DCC/NHS. 
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This process helped activate carboxyl groups in folic acid. Subsequently, SH-PEG-NH2 
was added to the reaction mixture and the mixture was incubated overnight at room 
temperature. This resulted in the synthesis of folate-PEG by formation of an amide bond 
between folate and SH-PEG-NH2. The product was dialyzed against water (MWCO: 
1kDa) and retrieved through lyophilization. 
5.3.2.2 DOX-hyd-PEG conjugate (hereafter referred to as DH conjugate): 
Synthesis of DOX-hyd-PEG was done in three steps. In the first step, SH-PEG-COOH 
was conjugated with hydrazine hydrate to yield SH-PEG-hydrazide as follows: SH-
PEG-COOH was dissolved in dichloromethane and reacted with hydrazine monohydrate 
in a molar ratio of 1:10. The resultant solution was allowed to react for 24h at room 
temperature and later washed with brine solution. The organic phase was collected and 
rotavaporized to yield SH-PEG-hydrazide. In the second step of the synthesis, SH-PEG 
hydrazide and DOX were reacted in an equimolar ratio in anhydrous methanol. Finally, 
the mixture was reacted in the presence of a drop of trifluoracetic acid in 60 °C 
overnight. After solvent removal, the residue was dissolved in water and further dialyzed 
against water for 24 h (MWCO: 1kDa, Spectrum Labs). 
5.3.2.3 DOX-cbm-PEG conjugate (hereafter referred to as DC conjugate): 
DOX-cbm-PEG was synthesized via an amide bond and used as a control. Briefly, SH-
PEG-COOH was reacted at room temperature overnight with triethylamine, DCC and 
DOX in dichloromethane. The resultant product was dialyzed against water (MWCO: 
1kDa). Later, the purified conjugate was lyophilized. 
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5.3.2.4 Characterization of Folate and DOX conjugates: 
All three conjugates were characterized through UV-visible spectroscopy and 1H-NMR 
spectroscopy. 
UV-visible absorption data was obtained for each of the polymer conjugates (FP, DH, 
and DC). Conjugate solutions were prepared in appropriate solvents (DMSO for FP and 
methanol for the DOX conjugates) and placed in 1.5 mL cuvettes. Samples were diluted 
to the linear absorption range (< 3 A.U.), and absorption spectra from 200 to 900 nm 
were recorded using a Cary Win UV spectrophotometer (Varian/Agilent Technologies, 
Switzerland). Automatic blank correction was performed using the corresponding 
solvent (DMSO or methanol). An approximate spectrophotometer warm up time of 30 
min before measurements was kept constant for all experiments. 
 
1H-NMR measurements were done on samples of FP, DH and DC all dissolved in 
deuterated DMSO. The 1H NMR spectra were recorded on a 400 MHz Avance Bruker 
NMR spectrometer using 240 scans. Acquired data was processed and analyzed using 
MestReNova software. Chemical shifts were reported in parts per million (ppm) for 1H 
NMR on δ scale based on the dimethyl sulfoxide-d6 solvent peak (δ = 2.5 ppm) as an 
internal standard. 
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5.3.2.5. Preparation of polymer conjugate-self assembled AgNPs: 
All the conjugates were solubilized in DMSO (1mg/ml). Equimolar concentrations of 
FP/DH and   FP/DC (corresponding to 1mg total) were respectively added onto 1 mg of 
citrate-stabilized AgNPs in 10 ml ultrapure water, and allowed to stir for 2h at room 
temperature in the dark. Thereafter, the nanoparticles were centrifuged at a speed of 
12500 rpm for 15 min to remove free polymer conjugates, and washed once with Milli-
Q water. The nanoparticles were designated as FHAgNPs (those functionalized with 
FP/DH) and FCAgNPs (those functionalized with FP/DC), respectively. The 
nanoparticles were characterized for size through UV-visible spectroscopy, Dynamic 
Light Scattering, and Transmission Electron Microscopy; for charge through zeta 
potential measurements; and for self- assembly of polymer conjugates through Surface-
Enhanced Raman Spectroscopy (SERS). 
5.3.2.6 Effect of pH on polymer self-assembled AgNPs: 
Self-assembled FHAgNPs and FCAgNPs were incubated with PBS (0.01 M) at pH 7.4 
and 5.0 respectively for 2h, 12h and 24h incubation times. The effect of pH on the 
polymer self-assembled AgNPs was analyzed through SERS.  
5.3.2.7. In vitro uptake of polymer self-assembled AgNPs: 
The concentration of silver in the silver colloids and the uptake of AgNPs in cancer cells 
was also estimated using Inductively Coupled Plasma- Optical Emission Spectroscopy 
(ICP-OES). In order to estimate the silver content in cells, cells were deproteinized by a 
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wet ashing procedure as described by Yong et al (Yong 2006). Briefly, FHAgNPs, 
FCAgNPs, FAgNPs (AgNPs self-assembled with FP but without DOX) and AgNPs 
(bare AgNPs) were incubated for 24 h with MES-SA, MES-SA/Dx5, SKOV3 and 
L1210 cells  (at a cell density of 100,000 cells/ ml) at a final concentration of 32.5 ppb. 
MES-SA and MES-SA/Dx5 are cell lines that do not overexpress folate receptor (i.e., 
are FR-), and SKOV3 and L1210 are cell lines that overexpress folate receptor (i.e, are 
FR+) (Spinella 1995; Zhang 2004). Thus, MES-SA and MES-SA/Dx5 serve as negative 
controls and SKOV3 and L1210 cells serve as positive controls. The cells were then 
lysed and a portion of the supernatant was utilized to measure the protein content of the 
cells, whereas the rest was utilized to measure the respective silver content. The in vitro 
uptake of nanoparticles was also assessed through Raman spectroscopy and fluorescence 
microscopy. 
5.3.2.8 SERS instrumentation and measurement: 
A PerkinElmer Raman microscope (Raman Micro 300) was used to acquire SERS 
spectra. The system uses a diode laser (785 nm) with an average power of 100 mW at 
the sample and 100- micron spot size. The spectra obtained were processed using built-
in software. All spectra were collected using a total laser exposure of 5-15 sec (4 
acquisitions each of 1-3 seconds each).  Briefly, a drop of sample was placed on a pre-
cleaned glass slide and focused using a 20x objective. The spectra were obtained from 
different locations of the drop (10 different locations were used to acquire each 
spectrum). To acquire intracellular SERS data, SKOV3 and MES-SA cells (which 
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served as positive and negative control respectively for folate targeting) were seeded at a 
cell density of 100,000 cells/ ml onto quartz coverslips coated with poly-lysine. 
Different cells were focused on using a 50x objective to acquire the SERS signal, and 22 
different cells from the same batch were used to acquire the spectrum. All experiments 
were repeated three times (n=3). 
For fluorescent images, MES-SA and SKOV-3 cells were seeded onto 12 mm coverslips 
in petri dishes with cell density of 100,000 cells/ml and allowed to adhere for 24 h. Cells 
were washed twice with PBS, and then incubated with free doxorubicin, FCAgNPs or 
FHAgNPs at equivalent doxorubicin concentration of 4 μM in complete RPMI 1640 
medium at 37 °C for 24h.  Cells were washed twice with ice-cold PBS and fixed with 
fresh 4% paraformaldehyde for 15 min at room temperature. The cells were 
counterstained with Hoechst 3322 stain for the cell nucleus following the manufacturer's 
instructions. The coverslips were mounted on glass microscope slides with a drop of 
antifade mounting media (Life technologies Co., USA) to reduce fluorescence 
photobleaching. The intracellular fluorescence localization was visualized under a Delta 
Vision Deconvolution Microscope (GE Healthcare, Inc., USA). The image ratios of the 
acquired fluorescence images were calculated by processing them with MATLAB® 
(The MathWorks Inc., Natick, MA, USA). Briefly, the intensity of each pixel was 
background subtracted and a region of interest was defined as comprising of pixels with 
above-background intensity. The ratio was further determined by normalizing the total 
pixel intensity of this region of interest to its area.  
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5.3.2.9 In vitro toxicity of polymer self-assembled AgNPs: 
Cell viability was measured using a Sulforhodamine B (SRB) assay (Invitrogen, 
Carlsbad, CA, USA). This assay is used to measure cellular protein after drug treatment 
(Monks 1991). In this study, FC AgNPs, FHAgNPs, and bare AgNPs (corresponding to 
a final silver concentration of 32.5 ppb and a final concentration of 4 μM DOX for the 
conjugates) were incubated with MES-SA, MES-SA/Dx5 and SKOV-3 cells for 24 
hours to evaluate their toxicity. The toxicity assessment procedure has already been 
described in detail in our previous report (Tang 2009). Mean absorbance was calculated 
from four wells corresponding to the same treatment and cell line. Mean (± S.D.) was 
determined from three different experiments. Cell growth fractions were measured by 
normalizing data corresponding to each treatment to their respective control. 
AgNPs have been shown to absorb NIR radiation and mediate toxicity through induction 
of reactive oxygen species (ROS) (Corato 2012). In this study, the cytotoxicity of six 
different treatments (AgNPs with and without laser treatment, FCAgNPs with and 
without laser treatment, FHAgNPs with and without laser treatment) were investigated. 
Cells were seeded onto a 96-well plate on the first day, and after overnight incubation 
were exposed to different treatments (each corresponding to a silver concentration of 
32.5 ppb and an equivalent DOX concentration of 4 µM for self-assembled 
nanoparticles).  
Cell viability 24h post-treatment was measured colorimetrically with an SRB assay 
which reports total protein. Average cell growth fractions were obtained from four wells 
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for each treatment (n=3). The data were acquired and represented in the same manner as 
the toxicity of the formulations discussed in the previous paragraph. 
5.3.2.10 Mechanism of toxicity of polymer self-assembled AgNPs 
5.3.2.10.1 Ag+ release from self-assembled polymer silver conjugate nanoparticles with 
and without laser:  
AgNPs and self- assembled AgNPs (FHAgNPs and FCAgNPs) were centrifuged and the 
supernatant was collected. To assess silver ion release after laser treatment, the 
nanoparticles were exposed to an 808-nm laser at fluence rate of 6.7 W/ cm2 for 3 min. 
After laser treatment, the nanoparticles were centrifuged and the supernatant fractions 
were collected. Silver ion release from each of the groups (AgNPs with and without 
laser treatment, and self-assembled nanoparticles with and without laser treatment) was 
measured by assessing the silver content of the respective treatment groups. Silver ion 
release was reported as dissolution percentage, which is the silver ion released 
normalized to the initial silver content of the nanoparticles. 
5.3.2.10.2. Intracellular ROS: 
Oxidative stress has been reported as one of the critical mechanisms of cytotoxicity 
induced by AgNPs (Foldbjerg 2009). To measure the intracellular generation of reactive 
oxygen species (ROS), MES-SA, MES-SA/Dx5 and SKOV-3 cells were seeded onto 
glass-bottom 96-well black well plates. After 24 h growth, the cells were treated with 
FCAgNPs, FHAgNPs and AgNPs with and without laser treatment. The cells were 
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further loaded with 10 μM fluorescent marker 2’, 7’-dichlorodihydrofluorescein 
diacetate (H2DCF-DA, Sigma, US) in RPMI 1640 for 30 min, then washed with PBS, 
and immediately used for fluorescence measurements and re-suspended in RPMI 1640 
without phenol red. All experiments were conducted in the dark. A 488-nm laser was 
used for excitation and fluorescence was detected by a 525/30 nm filter (for H2DCF-DA 
fluorescence). For each sample the mean fluorescence intensity was determined and 
further normalized to the respective cell growth fraction measured by SRB assay in 
order to determine intracellular production of ROS. 
5.3.2.10.3. Intracellular GSH and thiol levels: 
MES-SA, MES-SA/ Dx5 and SKOV-3 cells were seeded at a density of 100,000 cells/ 
ml. These cells were exposed to AgNPs, FCAgNPs and FHAgNPs at concentration of 
32.5 ppb, and then lysed and assessed for intracellular glutathione (GSH) and thiol 
concentrations using a GSH assay. Levels were normalized to control cells that were not 
subjected to any treatment.  
5.4 Results and Discussion: 
5.4.1. Preparation of AgNPs: 
AgNPs were synthesized using a method involving reduction of a silver salt in the 
presence of a reducing agent, citric acid. The formation of AgNPs was confirmed by 
UV-visible spectroscopy. These nanoparticles exhibit maximum surface plasmon 
absorbance at 435 nm (Bhardwaj 2013), and have a size of 70 nm determined through 
156 
 
TEM and charge of -40 mV. The nanoparticle size determined through TEM was 
consistent with that observed through DLS as seen in Figure 18. A small proportion of 
rods was seen, which is consistent with the literature (Faulds 2005). The negative charge 
of the AgNPs could be due to the presence of citrate molecules on the nanoparticle 
surface, again consistent with literature reports (Wang 2014).  
5.4.2. Preparation and characterization of polymer conjugates: 
Folic acid and DOX were conjugated to heterobifunctional PEG with sulfhydryl as an 
end group. Folate-PEG (FP) was synthesized by forming an amide bond between the α-
carboxylate group and the amine group of PEG. The α-carbon of folic acid was chosen 
for the reaction because it does not form a paratope to the folate receptor, and hence 
could be successfully used for conjugation without harming the targeting potential of the 
ligand (Chen 2013). 
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1H- NMR spectrum of DOX-cbm-PEG and DOX-hyd-PEG in DMSO-d6 showed 
characteristic DOX peaks at 7.9, 7.6, 5.3, 4.58, 4.0 ppm and characteristic PEG peak at 
3.6 ppm. The 1H- NMR spectrum of Fol-cbm-PEG in DMSO-d6 showed characteristic 
Folic acid peaks at 8.6, 7.7, 6.6, 4.5 and 4.3 ppm and characteristic PEG peak at 3.6 
ppm. Conjugate yield was 72% (FP), 84% (DC), and 72% (DH). The DOX content in 
DH and DC was estimated by breaking the amide and hydrazone bond in 1N HCl and 
estimating the amount of drug in the supernatant. DOX content was estimated to be 
5.5% w/w in DC and 8% w/w in DH. Huan and coworkers obtained similar DOX 
content in PEG-hyd-DOX and PEG-cbm-DOX (Huan 2012).  The reaction schemes of 
FP, DC and DH can be seen in Figure 21. The characteristics of FP, DC and DH are 
tabulated in Table 2. 
5.4.3. Preparation and characterization of polymer conjugate-self assembled AgNPs: 
Folate-PEG and DOX-PEG conjugates were self-assembled onto AgNPs through the 
sulfhydryl bond of heterobifunctional PEG. FH and FC nanoparticles had FP/DH and 
FP/DC conjugates self-assembled onto the nanoparticle surface in equimolar ratios. Self-
assembly was allowed so that the nanoparticles would retain their targeting abilities and 
at the same time have the active agents to exert synergistic chemo-photodynamic 
therapy. 
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                                     Table 2: Characterization of Fol-cbm-PEG (FP), DOX-cbm-PEG (DC) and DOX-hyd-PEG (DH) 
Polymer-
conjugate 
UV-vis 
characterization 
1H-NMR 
Characterization 
Fluorescence  
Fol-cbm-PEG 
(FP) 
Absmax@ λ=280 
nm, consistent with 
that of folic acid 
8.65 , 7.62 , 6.64 , 
4.49 and 4.29 ppm 
correspond to FA, 3.6 
ppm to PEG 
N/A 
DOX-cbm-
PEG 
(DC) 
DOX 7.61, 5.42 and 4.51 
ppm correspond to 
DOX,3.6 ppm 
correspond to PEG 
 λex (480–490 
nm), λem (≥515 
nm) 
DOX-hyd-PEG 
(DH) 
Absmax@ λ=480 
nm, consistent with 
that of DOX 
7.61 ,5.42 and 4.51 
ppm corresponds to 
DOX, 3.6 ppm 
corresponds to PEG 
 λex (480–490 
nm), λem (≥515 
nm) 
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The SERS features of FHAgNPs were compared with those of FAgNPs and DHAgNPs 
(self-assembled with DH); and the SERS features of FCAgNPs were compared with 
those of FAgNPs and DCAgNPs (AgNPs self-assembled with DC). The presence of a 
band at 240 cm-1 corresponds to the formation of Ag-S via cleavage of thiol bonds, 
further affirming successful conjugation of polymer conjugates onto AgNPs (Joo 1987). 
Thus, it can be concluded that there is successful self-assembly of the polymer 
conjugates onto the nanoparticle surface. This feature also allows us to probe the 
intracellular fate of these nanoparticles in a label-free manner. 
5.4.4. Effect of pH on polymer self-assembled AgNPs: 
FH AgNPs and FC AgNPs were incubated in two buffer solutions with different pH 
(PBS buffer with pH 7.4 and pH 5.0). A buffer with pH 5.0 was used because it 
emulates the pH of acidic endo-lysosomal compartments inside the cell. FH exhibited a 
time-dependent reduction in the peak corresponding to DOX at 1452 cm-1 when exposed 
to low pH 5.0 (Yan 1997). FC, on the other hand, retained the DOX peak over time (See 
Figures 22C and 22D). The supernatant obtained after exposing FHAgNPs to pH 5.0 in a 
time-dependent manner showed increasing concentrations of DOX. This difference in 
behavior could be attributed to the way the DOX is tethered to the two types of 
nanoparticles. In FCAgNPs, DOX is bonded to the nanoparticles through a strong amide 
bond, whereas in FHAgNPs, DOX is tethered through an acid-labile hydrazone bond. 
This method of pH-triggered release of drug from nanoparticles has been reported by  
several other researchers (Wang 2011 ; Huan 2012). An amide bond is a relatively 
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strong bond which requires extreme pH environments (pH 1-2) to break. A hydrazone 
bond, on the other hand, takes up the free H+ ions in media having low pH, and in the 
process it releases free DOX, converting DOX-hydrazone-PEG back to its original PEG-
hydrazide form (Yoona 2010). 
 
Table 3.  Band assignment of spectra of FAgNPs, FCAgNPs and DCAgNPs 
FAgNPs DCAgNPs FCAgNPs Band Assignment Molecule 
1620   1620 
C=C stretch, C=O 
stretch Folic acid (FA) 
1582   1582 
Ring stretch (aromatic 
ring) Folic acid (FA) 
1495   1495 NH2 bend and wagging Folic acid (FA) 
1471   1471 ʋring  Folic acid (FA) 
1452 1453 1455 CH2 deformation 
Doxorubicin (DOX) and Folic 
acid (FA) 
  1428 1428 (δas(CH3)) Doxorubicin (DOX) 
1396 1394 1396 
CH rocking vibration, 
CH2 deformation Polyethylene glycol (PEG) 
  1316 1316 CH3 bending Doxorubicin (DOX) 
1234 1234 1234 C-O stretch, ʋ(C-C) Polyethylene glycol (PEG) 
1175   1175 CH2 rocking vibrations Folic acid (FA) 
1130 1129 1126 Trans C-C stretch Polyethylene glycol (PEG) 
1034 1034 1034 δ(C-H), ʋ(C-O) stretch Polyethylene glycol (PEG) 
855 855 855 ʋ(C-C) stretch Polyethylene glycol (PEG) 
690   690 C-H vibrations Folic acid (FA) 
560 560 560 C-H torsion Polyethylene glycol (PEG) 
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Table 4: Band assignment of spectra of FAgNPs, FHAgNPs, and DHAgNPs 
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alter the receptor-mediated endocytosis of the nanoparticles. These results are consistent 
with Wang et al (Wang 2011 ).  
The similar uptake of both FH and FC nanoparticles in FR+ cells after 24 h incubation 
suggests different mechanisms for their different intracellular fates. SERS spectra (Figure 
22F) and fluorescence images (Figure 24) demonstrate that DOX can be released from 
FHAgNPs in response to the intracellular acidic micro-environments after 24 h 
incubation.  Cellular entry through the acidic endo-lysosome compartment is the 
prerequisite for the cleavage of the hydrazone bond, which results in DOX release. Figure 
22F shows SERS spectra acquired from FHAgNPs incubated with SKOV-3 for 24 h. The 
SERS spectra demonstrate an absence of a DOX peak at 1452 cm-1, consistent with SERS 
spectra of FHAgNPs incubated in PBS at pH 5.0. The SERS spectral results are 
consistent with the fluorescence images wherein FH nanoparticles exhibit higher 
intracellular fluorescence than FC nanoparticles. Further, the SERS spectra of FC 
nanoparticles in SKOV-3 incubated for 24 h retained the DOX peaks (Figure 22E), and 
these results are again consistent with the fluorescence images of FC in SKOV-3 (Figure 
24).  The reductive environment of cells (i.e. high intracellular thiol concentration) may 
mediate release of the self-assembled polymers from nanoparticles, and the Ag-S bond 
linking the polymer conjugate to AgNPs is more stable than the hydrazone linkage. 
Further, the reductive environment of the cells is predominant only in the cytoplasm and 
not in the acidic compartments, thus asserting the fact that the predominant factor 
affecting drug release from FH nanoparticles was intracellular pH. As a result, 
intracellular fluorescence was found to be higher in SKOV-3 cells incubated with FH 
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FH nanoparticles and free DOX in MES-SA (FR-) and SKOV3 (FR+) cells by 
fluorescence images is shown in Figure 24.  The images show higher intracellular 
fluorescence from FH nanoparticles than from FC nanoparticles in both MES-SA and 
SKOV-3 cells (FR- and FR+ cells, respectively). The higher intracellular fluorescence 
from FH nanoparticles could be due to the release of DOX from FH through acid-labile 
hydrazone bonds in the acidic endo-lysosomal compartment in the cells. Fluorescence is 
mainly seen in the perinuclear space and less in the nucleus. These results are consistent 
with Wang et al, who reported a similar perinuclear distribution of DOX released from 
DOX-tethered gold nanoparticles through hydrazone bond after 24 h incubation (Wang 
2011 ). 
5.4.6 In vitro toxicity of polymer self-assembled AgNPs: 
The above data demonstrated enhanced cellular drug accumulation of acid-responsive FH 
nanoparticles due to rapid release of tethered drug. FHAgNPs exhibited significantly 
higher toxicity than FCAgNPs and AgNPs in FR+ SKOV-3 and L1210 cells in 
comparison to their FR- counterparts (MES-SA and MES-SA/Dx5 cells). This could be 
due to higher uptake of FH nanoparticles through receptor-mediated endocytosis and 
respective higher release of DOX in FR+ cells. FCAgNPs, on the other hand, are not acid 
responsive and did not generate significantly different toxicity levels in comparison to 
their non-targeted counterparts in either FR+ or FR- cells (See Figure 25A). 
171 
 
 
 
 
 
 
 
 
 
 
Table 5: Band assignment of intracellular SERS data of FHAgNPs (or FH) and FCAgNPs (or FC) in SKOV-3 cells 
Raman 
band 
(cm-1) Band assignment Depiction Meaning 
1580 
Ring stretch (aromatic 
ring) 
Corresponds to FH AgNPs  and FCAgNPs 
outside and inside cells   
1453 (δas(CH3) 
DOX peak absent in FHAgNPs and present in 
FCAgNPs inside cells 
Depicts intracellular 
DOX release in case 
of FH AgNPs  
1130 Trans C-C stretch 
Corresponds to FH AgNPs and FCAgNPs 
outside and inside cells 
Positive sign of 
uptake 
850 ʋ(C-C) stretch 
Corresponds to FHAgNPs and FCAgNPs 
outside and inside cells 
Positive sign of 
uptake 
1300 Phospholipid band 
Decreased in spectra of FHAgNps and 
FCAgNPs compared to that of AgNPs inside 
cells  
Shows positive signs 
of apoptosis 
1160 DNA band 
Decreased in spectra of FHAgNps and 
FCAgNPs compared to that of AgNPs inside 
cells  
Shows positive signs 
of apoptosis 
1060 Phospholipid band 
Decreased in spectra of FHAgNps and 
FCAgNPs compared to that of AgNPs inside 
cells  
Shows positive signs 
of apoptosis 
1110 Amide III 
Increased in spectra of FHAgNPs compared to 
that of AgNPs inside cells 
Shows positive signs 
of apoptosis 
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These results are consistent with Guo et al., who reported similar enhanced toxicity of 
FA-PECL-hyd-DOX nanoparticles in folate-overexpressing cancer cells in comparison to 
folate receptor negative cells (Guo 2013). After incubation with FHAgNPs, FCAgNPs, 
and AgNPs, cells were subjected to NIR laser to examine the photodynamic effect of 
nanoparticles on cells. FHAgNPs, when exposed to NIR laser (808 nm, fluence rate 6.7 
W/cm2), enhanced the toxicity by a factor of two in comparison to bare AgNPs in L1210 
and SKOV-3 (FR+) cell lines.  
The negative controls exhibited comparable cytotoxicity after exposure to laser. The 
maximum plasmon absorption of AgNPs is at 435 nm; however, there is sufficient light 
absorption at much higher wavelengths (as in our case at 808 nm). This observation of 
light at higher wavelengths could be due to the close distance between individual 
nanoparticles that results in coupling of plasmons of adjoining nanoparticles.  
Corato and coworkers reported similar toxicity of AgNPs embedded in magnetic beads 
upon NIR laser illumination (830 nm, fluence rate of 7.7 mW/µm2, 5min) (Corato 2012). 
The fluence rate used in our experiment is several folds less than that used by Corato and 
coworkers. This helps in generation of cytotoxic levels of silver ions that can be 
synergistic along with the application of chemotherapy. Additionally, the NIR laser 
treatment alone at the fluence rate used in our experiments has shown no adverse effect 
on cells (Srinivasan 2014). Guo and coworkers also reported significantly lesser toxicity 
of FA-PECL-cbm-DOX nanoparticles in comparison to FA-PECL-hyd-DOX 
nanoparticles in both folate receptor overexpressing and receptor negative cell lines (Guo 
2013). 
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Chemotherapeutic drugs such as DOX are mostly limited in their application due to non-
specificity to tumors. Thus, these molecules require a suitable delivery vehicle with 
unique properties such as small size, low toxicity, and ease of surface functionalization. 
Based on these desirable characteristics, AgNPs can serve as potential candidates for 
delivery of DOX. Further, employing pH-mediated release helps enhance intracellular 
delivery of the chemotherapeutic agent. It is worth noting that the PEG spacer could 
potentially prolong circulation and eventually increase tumor accumulation through the 
enhanced permeation and retention effect in vivo.  
In summary, the acid-responsive behavior of both FH and FC nanoparticles was assessed 
both extracellularly and intracellularly through Raman and fluorescence spectroscopy. 
Further, we observed that pH-sensitive FH nanoparticles exhibit enhanced toxicity upon 
laser exposure, thus showing a synergistic chemo-photodynamic effect.  
The mechanism behind the toxicity of FH and FC nanoparticles with and without laser 
exposure was assessed through three different methods as described below. 
5.4.7. Ag+ release from self-assembled polymer silver conjugate nanoparticles with and 
without laser: 
The most widely reported cytotoxicity mechanism of AgNPs is the release of Ag+ ions 
from its surface which results in the generation of reactive oxygen species (ROS) and 
depletion of intracellular thiol and glutathione (GSH) concentrations (Mukherjee 2014).  
We studied the release of Ag+ ions from the surface of these nanoparticles under 
different conditions, in order to understand the toxicity mechanisms of self-assembled 
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nanoparticles (FHAgNPs) and citrate-stabilized (AgNPs) AgNPs. The release of metallic 
ions from the surface of metal nanoparticles depends on different factors such as capping 
agent, medium pH, incubation time, and incubation temperature, which further aid in 
induction of reactive oxygen species (ROS) (Liu 2010). AgNPs exhibited a silver ion 
release of 11% in cell-culture medium after 24 h incubation. Corato and coworkers 
showed similar levels of silver ion release (16%) from AgNPs in cell culture medium 
(Corato 2012). FHAgNPs exhibited a significant reduction in silver ion release in cell 
culture medium with the same incubation time. This reduction in silver ion release from 
the nanoparticle surface could be due to the presence of a thiol-ended polymer conjugate 
self-assembled onto the nanoparticle surface. Binding of silver to thiol compounds drive 
free silver ion (Ag+) to very low concentrations (Pokhrel 2013). FHAgNPs and AgNPs 
exhibited similar silver ion release after NIR laser exposure (See Figure 25B). This can 
be explained if the laser at the given fluence would either dislodge the thiol-capping from 
the nanoparticle surface, or if silver ions were released through the pores of the polymer 
self-assembled onto the AgNPs. SERS-based experiments were conducted where the 
presence of thiol-capping on AgNPs was assessed before and after laser irradiation. The 
results showed that laser irradiation did not disrupt the Ag-S bond, as there was no 
change in Surface Enhanced Raman spectroscopy data after laser irradiation. Thus, pore-
mediated release as discussed above seems to be a more feasible explanation, although it 
would need to be explored in further detail in the future.   
5.4.8. Intracellular GSH and thiol levels: 
Glutathione (GSH) and intracellular thiol molecules serve as major intracellular 
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antioxidant scavengers that protect cells from oxidative stress through binding with ROS. 
Thus, reduction of GSH-mediated antioxidant defense systems is critical for cell death 
(Sies 1999.). Better outcomes can be obtained by using therapeutic modalities that can 
enhance ROS production and deplete intracellular antioxidant defenses, rather than using 
just one of the methods (intracellular ROS generation or intracellular GSH depletion). 
Our AgNPs and silver conjugates have shown significant reduction of GSH and 
intracellular thiol concentrations in comparison to control cells with no treatment (see 
Figures 25C and 25D). FHAgNPs also exhibited a significant reduction of GSH and 
intracellular thiol concentrations in comparison to FCAgNPs and AgNPs in FR+ cancer 
cells. The negative controls exhibited similar reductions of GSH and thiol concentration. 
These results are consistent with Piao et al and Mukherjee et al, who also reported similar 
intracellular glutathione depletion in cells subjected to silver nanoparticle treatment (Piao 
2011; Mukherjee 2014). 
5.4.9. Intracellular ROS: 
Reactive oxygen species (ROS) are regularly generated in small amounts in all biological 
systems, and they are constantly eliminated from the system through anti-oxidant defense 
mechanisms. When generated in excessive amounts, ROS can induce DNA mutations 
that may result in the initiation of apoptosis leading to cell death (Mate 2000). Our 
experimental results shown in Figure 25E indicate that FHAgNPs exhibit significant ROS 
generation in comparison to both FCAgNPs and AgNPs before and after laser irradiation 
in FR+ SKOV-3 cells. These results indicate the possibility of ROS being generated by 
DOX released from nanoparticles, as DOX has been investigated for its ROS generation 
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capacity (Gouaze 2001). The enhanced uptake of FHAgNPs and enhanced release of 
DOX in these cells could provide an explanation for the enhanced ROS production in 
FR+ cells. All AgNPs and conjugates exhibited higher ROS production after laser 
irradiation, due to the possible release of silver ions as discussed in section 5.3.7. The 
negative controls MES-SA and MES-SA/Dx5 did not exhibit significant ROS production 
from FHAgNPs, FCAgNPs and AgNPs before and after laser irradiation. The 
intracellular ROS data is hence consistent with the cytotoxicity and silver ion release 
data.  
                               Conclusions: 
We successfully prepared the polymer conjugates FP (folate-PEG conjugate by means of 
an amide bond), DH (DOX-PEG conjugate by means of an acid-labile hydrazine bond) 
and DC (DOX-PEG conjugated by means of an amide bond), and self-assembled these 
polymer conjugates onto AgNPs to form FHAgNPs FP and DH self-assembled onto 
AgNPs), and FCAgNPs (FP and DC self-assembled onto AgNPs). FHAgNPs and 
FCAgNPs exhibited specific targeting potential in SKOV-3 and L1210 cells that 
overexpress folate receptors. FHAgNPs exhibited pH-triggered drug release inside cells. 
These nanoparticles also exhibited enhanced toxicity upon laser exposure, thus showing 
great promise for combinatorial treatment employing both chemotherapy and 
photodynamic therapy. Future work will involve exploring their potential for 
simultaneous photodynamic and chemotherapy treatment in vivo. 
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CHAPTER 6: OVERALL CONCLUSION, LIMITATIONS AND SCOPE FOR 
FUTURE WORK: 
There is an increasing interest in the development of multifunctional agents for cancer 
management with the intent of improving diagnostics and therapy for cancer patients. 
Nanotechnology serves as a unique platform where both diagnostic and therapeutic 
agents can be combined into a single platform, in what has been termed a theranostic 
approach. Recent advances in the field of nanotechnology have led to increased interest 
in research and development of these theranostic agents, and on making them suitable for 
personalized medicine by modifying their size, charge, and other physicochemical 
properties. This method of delivering diagnostic and therapeutic agents simultaneously, 
including the subfield of image-guided therapy, can help to better diagnose and treat a 
heterogeneous disease such as cancer, with the potential to detect and eradicate tumor 
tissue in its earlier stages. These agents can be further tailored to specifically target 
cancer cells that overexpress particular receptors, thus allowing for targeted therapy. 
It has been found that no one treatment modality can be utilized to treat cancer, and in a 
clinical scenario it is most common for two or more modalities to be used to completely 
eradicate a tumor. Phototherapy has been used as a mode of cancer therapy, serving as an 
adjuvant treatment to conventional treatment modalities such as chemotherapy and 
radiotherapy.   
In this project, we chose to study two multifunctional nanoparticle systems for targeted 
combined chemo-phototherapy, and we also tried to understand the cellular response to 
these nanoparticles. The overarching goal of the project was to prepare multifunctional 
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nanoparticles for combined theranostics, as well as to understand the different 
mechanisms and effects that derive from utilization of different multifunctional designs. 
We also evaluated drug delivery strategies with different co-therapy types, by designing 
two nanoparticle formulations that contained DOX as a chemotherapy agent but where 
one formulation used photothermal therapy, and the other used photodynamic therapy as 
the combinatorial therapy. A complete understanding of how to apply these 
multifunctional systems in vivo requires the exploration of their cellular response, which 
would throw light on appropriate choices of treatment strategies, such as optimal timing 
for therapy.  
In the chemotherapy-photothermal therapy approach, we prepared a multifunctional 
nanoparticle system by the simultaneous entrapment of a near-infrared light-activatable 
agent (ICG) and a chemotherapeutic drug (DOX) into polymeric nanoparticles. Several 
researchers have investigated the potential of multifunctional inorganic nanoparticles for 
targeted combined chemo-photothermal therapy, such as mesoporous silica encapsulated 
gold nanorods (Shen 2013), folic acid conjugated graphene oxide for chemo-
photothermal therapy (Qin 2013), and hollow gold nanospheres entrapped with DOX 
(You 2010). However, polymeric biomaterials are preferable for drug delivery due to 
their biodegradability and ease of manipulation for efficient and controlled drug release 
(Nair 2007). PLGA is an FDA-approved polymer for drug delivery applications with 
several positive attributes such as ease of manipulation of monomer ratio or polymer 
weight, as well as biologically harmless metabolites (Danhier 2012), and hence was 
chosen for the study. These PLGA nanoparticles with entrapped ICG and DOX were 
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surface-decorated with anti-Human Epithelial Receptor-2 in order to specifically target 
the corresponding receptors overexpressed on cancer cells. Indeed, we observed an 
enhanced uptake of these nanoparticles in SKOV-3, which are cancer cells that 
overexpress these receptors. We also saw an enhanced cytotoxic effect of these 
nanoparticles upon laser irradiation (as ICG showed hyperthermia capabilities upon laser 
irradiation), which indicated that they have potential for targeted chemo-hyperthermia 
applications.  
We further investigated the cellular response upon exposure of these nanoparticles to two 
different heat modalities: laser therapy and incubator hyperthermia. We chose the two 
different hyperthermia modes to mimic the approaches used in a clinical setting, i.e., 
localized and whole body hyperthermia. HSP70 (an anti-apoptotic protein) and caspase-3 
(pro-apoptotic protein) were chosen to study their expression kinetics upon nanoparticle 
administration. These two proteins were used for the study because combinational 
therapy based on photothermal therapy has been shown to cause aggregation and 
denaturation of cellular proteins by affecting their folding.  Intracellular protein synthesis 
is decreased in a dose-dependent manner upon exposure to temperatures between 42 and 
45 °C. When cells undergo heat stress, there is an increase in expression of heat shock 
proteins. These are molecular chaperone proteins that increase cell survival by preventing 
the disaggregation of folded proteins and degrading damaged proteins (Hildebrandt 
2002). However, when cellular damage goes over a threshold limit,  heat shock protein 
expression becomes downregulated, and cells will undergo death by means of apoptosis 
or necrosis depending on the degree of thermal insult. Understanding the expression 
kinetics of apoptotic and anti-apoptotic proteins helps elucidate possible cellular fate and 
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mechanisms of death, and may also provide insights into future treatment targets that 
focus on key players in death pathways. .  
In our study, we found that cells showed a faster heat shock response when exposed to 
nanoparticles and laser irradiation in comparison to exposure to nanoparticles and 
incubator hyperthermia. Based on our caspase-3 expression results, we also showed that 
cells underwent necrotic death upon exposure to nanoparticles and laser irradiation, 
versus apoptotic death upon exposure to nanoparticles and incubator hyperthermia. .  
One of our overarching goals was to gain an insight into the differences between 
combinatorial chemotherapy-phothothermal therapy and chemotherapy-photodynamic 
therapy. Therefore, we formulated nanoparticles that could exert a photodynamic effect 
as well as entrap DOX. For combinatorial chemotherapy-photodynamic therapy, metal 
nanoparticles such as gold and silver were an appropriate choice due to their unique 
optical properties and their ability to be utilized as drug delivery vehicles. We selected 
silver because it exhibited several positive attributes over gold such as higher extinction 
coefficients, sharper extinction bands, higher ratio of scattering to extinction, and 
extremely high field enhancements (Carlos Caro 2010). Gold nanoparticles have also 
been investigated for application in combined chemo-photodynamic therapy (Li 2015), 
however, silver nanoparticles have better photodynamic activity than gold nanoparticles 
(Vankayala 2013). Several researchers have also investigated the potential application of 
organic dyes as photosensitizers when used in conjunction with chemotherapy. For 
instance,  Peng and coworkers investigated the potential of chlorin-core micelles with 
simultaneously entrapped hydrophobic drugs and photosensitizer SN-38 for combined 
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chemo-photodynamic therapy in a HT-29 human colon cancer xenograft model (Peng 
2009), and Nahabedian and cowokers studied the interaction of the PDT agent 
hematoporphyrin derivative and DOX in a murine tumor model (Nahabedian 1988). 
However, organic dye-based photosensitizers suffer from the limitation of potential 
photobleaching.  
 Therefore, in the chemotherapy-photodynamic therapy approach, we created a different 
set of targeted multifunctional silver nanoparticles where the nanoparticle itself can serve 
as a phototherapeutic agent and would entrap the same chemotherapy agent, DOX. We 
functionalized the surface of AgNPs by attaching folic acid and DOX via a PEG spacer. 
Folic acid was attached to the PEG spacer through an amide bond, and DOX through a 
pH-sensitive bond. This design allowed for pH-triggered release of DOX. Silver 
nanoparticles exhibited a photodynamic effect upon laser exposure and showed enhanced 
cytotoxicity upon laser exposure, thus demonstrating potential for targeted chemo-
photodynamic therapy applications. Silver nanoparticles are photosensitizers which affect 
the cellular redox balance.  Loss of redox homeostasis has been implicated in 
tumorigenesis, with an imbalance between the cell’s antioxidant defense system (such as 
gluthathione or thiol) and the production of reactive oxygen species (Acharya 2010). 
Potentially, targeting redox status can provide a pathway to destroy cancer cells. 
Therefore, we also studied the cellular response of our multifunctional nanoparticles, 
which includes enhanced ROS production and reduction of intracellular thiol levels upon 
nanoparticle exposure. The rationale for investigating these markers was that 
combinational therapy using photodynamic therapy will affect the redox status of the cell.  
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Both of the formulations we created are novel approaches to combinatorial therapy which 
have potential for targeted cytotoxic effects, enhanced therapeutic effect brought about by 
the simultaneous application of chemotherapy and phototherapy on cancer cells, and 
theranostic capabilities that can be exploited for treatment monitoring. These 
nanoparticles serve as unique multifunctional platforms where more than one therapeutic 
modality can be used to treat tumors. This is certainly consistent with current clinical 
approaches to cancer management, which typically combine more than one treatment 
modality. The therapeutic combination of chemotherapy and phototherapy has been 
shown to possess synergistic effect (Tang 2009), which justifies the creation of 
multifunctional platforms where both these modalities can be delivered simultaneously to 
enhance outcomes. Our work can also help inform future researchers when developing 
new nanoparticle formulations or refining existing designs. Studying two different 
multifunctional nanoparticle formulations with different forms of combinational therapy 
enabled us to better understand cellular response to co-therapy, including the combined 
effects of chemotherapy and photothermal or photodynamic therapy. We were also able 
to investigate the different mechanisms underlying each of the two approaches in term of 
cell response to therapy, as well as their sensing capabilities for theranostic applications, 
and the potential advantages and limitations of each of the nanoformulations. These 
studies will also help in progressing towards in vivo biodistribution and efficacy testing, 
and also help researchers to understand the fundamentals of these novel platforms for 
further usage in conjunction with other treatment modalities 
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Every study suffers from some limitations and hence further research is generally 
required. Similarly, our study also has certain limitations that need to be kept in mind and 
improved by further research. The following limitations were observed: 
1) In specific aim #1: PLGA nanoparticles were utilized to simultaneously entrap 
hydrophilic ICG and hydrophobic DOX. However, the resulting nanoparticle formulation 
resulted in faster release of ICG than DOX. Therefore, a formulation that can result in 
slower release of ICG (probably conjugating ICG through a labile bond to the polymeric 
matrix) will be more helpful and further research needs to be done in this regard. 
2) In specific aim #2: Anti-apoptotic protein HSP70 and apoptotic protein caspase-3 
expression kinetics were studied during laser-phototherapy-chemotherapy and incubator-
phototherapy-chemotherapy. In future studies, molecular profiling using many more 
apoptotic and anti-apoptotic proteins (such as Bax or Bcl-2) should be employed to 
achieve a better understanding of the efficacy of the treatment. Further, the free drugs and 
nanoparticles should be investigated on in vivo tumor models, and the anti-apoptotic and 
apoptotic proteins should be retrieved from tissue sections after exposure to accurately 
measure protein expression in vivo. 
3) In specific aim #3: The method of purification of polymer conjugates was 
dialysis. A more extensive purification of the polymer-conjugates needs to be done in 
order to obtain the active extract. The system also needs to be evaluated in vivo to assess 
its in vivo efficacy.  
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4) In general: Additional chemical modifications in the nanoparticle formulations 
could be used to facilitate endo-lysosomal escape, and to incorporate specific intracellular 
targeting potential based on the desired target organelle. 
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